UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~September~~March 3031, ~~2019~~2020

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-38814

Positive Physicians Holdings, Inc.

(Exact Name of Registrant as Specified in its Charter)

Pennsylvania	83-0824448
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
100 Berwyn Park, Suite 220 850 Cassatt Road, Berwyn, PA	19312
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (888) 335-5335

Securities registered pursuant to Section 12(b) of the Act.

Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock	PPHI	The Nasdaq Stock Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐

Non-accelerated filer	☐	Smaller reporting company	☒

Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of ~~November~~June 1219, ~~2019~~2020, the registrant had 3,615,500 shares of common stock, $0.01 par value per share, outstanding.

Table of Contents

		Page
PART I.	FINANCIAL INFORMATION	1
Item 1.	Financial Statements (Unaudited)	1
	Unaudited Consolidated Balance Sheets	1
	Unaudited Consolidated Statements of Operations	2
	Unaudited Consolidated Statements of Comprehensive Income (Loss)	3
	Unaudited Consolidated Statements of Stockholders’ Equity	4
	Unaudited Consolidated Statements of Cash Flows	5
	Notes to Unaudited Consolidated Financial Statements	6
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	2120
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	32
Item 4.	Controls and Procedures	33
PART II.	OTHER INFORMATION	34
Item 1.	Legal Proceedings	34
Item 1A.	Risk Factors	34
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	34
Item 3.	Defaults Upon Senior Securities	34
Item 4.	Mine Safety Disclosures	34
Item 5.	Other Information	34
Item 6.	Exhibits	35
Signatures		3736

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements.

Positive Physicians Holdings, Inc.

Consolidated Balance Sheets

	September 30, 2019			December 31, 2018
	March 31, 2020			December 31, 2019
	(Unaudited)			~~(Unaudited Combined)~~
Assets
Available-for-sale bond securities, at fair value	$	93,238,702		$	85,206,669
Available-for-sale fixed maturity securities, at fair value	$	89,801,987		$	95,748,042
Equity securities, at fair value		75,~~351~~868,~~646~~709			7,~~267~~756,~~094~~966
Other investments, at net asset value		3,320,010			4,051,399
Short-term investments, at fair value		647,200			1,169,472
Short-term investments, at fair value		1,717,887			373,949
Total investments		96,317,896			104,674,480
Total investments		105,628,245			96,899,111
Cash and cash equivalents		21,918,875			20,988,081
Cash and cash equivalents		18,686,959			3,903,620
Accrued investment income		674,081			699,087
Accrued investment income		650,568			627,213
Premiums receivable		7,203,757			7,383,876
Premiums receivable		4,738,471			6,623,172
Reinsurance recoverable		8,630,126			7,850,409
Reinsurance recoverable		8,930,866			7,956,043
Income taxes recoverable		1,974,843			1,313,935
Income taxes recoverable		1,298,124			1,297,757
Unearned ceded premiums		211,086			1,181,345
Unearned ceded premiums		1,326,987			573,379
Deferred acquisition costs		2,968,462			2,584,486
Deferred acquisition costs		2,744,340			3,985,193
Deferred income taxes		1,164,235			891,584
Deferred income taxes		1,052,288			1,676,091
Prepaid management fee		8,571,428			8,928,571
Prepaid management fee		9,285,714			—
Other assets		3,286,957			124,507
Other assets		238,092			486,615
Total assets	$	152,921,746		$	156,620,361
Total assets	$	154,580,654		$	124,028,194
Liabilities and Stockholders' Equity
Liabilities
Losses and loss adjustment expenses	$	6564,~~953~~353,~~934~~351		$	6863,~~392~~607,~~333~~975
Unearned premiums		1214,~~092~~600,~~422~~188			1312,~~202~~783,~~626~~124
Reinsurance payable		1,~~865~~458,~~933~~132			1,~~203~~961,~~027~~653
Accounts payable, accrued expenses, and other liabilities		12,~~600~~179,~~566~~226			35,~~805~~009,~~354~~346
Note payable		8048,~~703~~854			~~127~~64,~~327~~858
Due to affiliates		141,733			309,310
Total liabilities		82,639,751			83,426,956
Total liabilities		81,735,291			87,039,977
Stockholders' Equity
Common stock, $0.01 par value, 10,000,000 shares authorized; 3,615,500 shares issued and outstanding		36,155			—36,155
Additional paid-in capital		49,~~421~~468,~~081~~496			1549,~~882~~421,~~835~~081
Retained earnings		2120,~~861~~973,~~202~~744			22,~~335~~096,~~398~~447
Accumulated other comprehensive income (loss)		1(196,~~526,925~~400	)		(1,~~230~~639,~~016~~722	)
Total stockholders' equity		7270,~~845~~281,~~363~~995			3673,~~988~~193,~~217~~405
Total liabilities and stockholders' equity	$	~~154~~152,~~580~~921,~~654~~746		$	~~124~~156,~~028~~620,~~194~~361

The accompanying notes are an integral part of these consolidated financial statements.

Positive Physicians Holdings, Inc.

Consolidated Statements of Operations

	Three Months Ended September 30,						Nine Months Ended September 30,
	Three Months Ended March 31,
	2019			2018			2019			2018
	2020			2019
	(Unaudited)			(Unaudited ~~Combined~~)			~~(Unaudited)~~			~~(Unaudited Combined)~~
Revenues
Net premiums earned	$	64,~~989~~684,~~910~~710		$	5,~~293~~491,~~656~~207		$	~~17,809,111~~		$	~~16,485,313~~
Net investment income		~~770~~766,~~007~~297			~~663~~628,~~577~~256			~~2,164,510~~			~~1,914,610~~
Realized investment (losses) gains, net		(~~115~~1,~~893~~964,421	)		~~225~~851,~~493~~651			~~909,376~~			~~248,743~~
Total revenues		73,~~644~~486,~~024~~586			6,~~182~~971,~~726~~114			~~20,882,997~~			~~18,648,666~~
Expenses
Losses and loss adjustment expenses, net		43,~~121~~185,~~056~~603			3,~~764~~321,~~202~~676			~~11,710,172~~			~~11,752,286~~
Other underwriting expenses		32,~~466~~338,~~905~~904			3,~~012~~500,~~002~~377			~~9,752,342~~			~~8,969,413~~
Interest expense		~~912~~595			1,~~556~~366			~~2,691~~			~~5,028~~
Total expenses		75,~~588~~525,~~873~~102			6,~~777~~823,~~760~~419			~~21,465,205~~			~~20,726,727~~
Income (loss) before provision for income taxes		55(2,~~151~~038,516	)		~~(595~~147,~~034~~695	)		~~(582,208~~	)		~~(2,078,061~~	)
Provision for income taxes		60(915,~~189~~813	)		~~(121~~55,~~634~~906	)		~~(108,012~~	)		~~(459,016~~	)
Net loss	$	(5,038	)	$	(473,400	)	$	(474,196	)	$	(1,619,045	)
Net income (loss)	$	(1,122,703	)	$	91,789
Loss per common share
Income (loss) per common share
Common stock - basic	$	(0.0031	)	$	—0.03		$	~~(0.13~~	)	$	—
Common stock - diluted	$	(0.0031	)	$	—0.03		$	~~(0.13~~	)	$	—
Common stock - basic and diluted	$	(0.00	)	$	—		$	(0.13	)	$	—

The accompanying notes are an integral part of these consolidated financial statements.

Positive Physicians Holdings, Inc.

Consolidated Statements of Comprehensive Income (Loss)

	Three Months Ended September 30,						Nine Months Ended September 30,
	Three Months Ended March 31,
	2019			2018			2019			2018
	2020			2019
	(Unaudited)			(Unaudited ~~Combined~~)			~~(Unaudited)~~			~~(Unaudited Combined)~~
Net loss	$	(5,038	)	$	(473,400	)	$	(474,196	)	$	(1,619,045	)
Net income (loss)	$	(1,122,703	)	$	91,789
Other comprehensive income (loss), net of tax:
Unrealized gain (loss) on available-for-sale bond securities:
Unrealized (loss) gain on available-for-sale fixed maturity securities:
Unrealized holding gain (loss) during the period, net of income tax (expense) benefit of $(111,475) and $33,962 for three months ended September 30, 2019 and 2018 and $(732,859) and $418,862 for nine months ended September 30, 2019 and 2018, respectively		429,346			(111,068	)		2,738,677			(1,563,056	)
Unrealized holding (loss) gain during the period, net of income tax benefit (expense) of $488,084 and $(344,205)		(1,797,079	)		1,266,592
Reclassification adjustments for (gains) losses included in net loss, net of income tax (expense) benefit of $(2,653) and $(4,437) for three months ended September 30, 2019 and 2018 and $4,856 and $(3,516) for nine months ended September 30, 2019 and 2018, respectively		(9,984	)		(16,691	)		18,264			(13,226	)
Reclassification adjustments for (gains) losses included in net income (loss), net of income tax (expense) benefit of $(10,379) and $7,515		(39,043	)		28,270
Other comprehensive income (loss)		~~419~~(1,~~362~~836,122	)		~~(127~~1,~~759~~294,862	)		~~2,756,941~~			~~(1,576,282~~	)
Comprehensive income (loss)	$	~~414~~(2,~~324~~958,825	)	$	~~(601~~1,~~159~~386,651	)	$	~~2,282,745~~		$	~~(3,195,327~~	)

The accompanying notes are an integral part of these consolidated financial statements.

Positive Physicians Holdings, Inc.

Consolidated Statements of Stockholders’ Equity

	Three Months Ended September 30, 2019 (Unaudited)
	Three Months Ended March 31, 2020 (Unaudited)
	Common Stock		Additional Paid-in Capital		Retained Earnings			Accumulated Other Comprehensive Income (Loss)			Total Equity
Balance, July 1, 2019	$	36,155	$	49,421,081	$	21,866,240		$	1,107,563		$	72,431,039
Balance, January 1, 2020	$	36,155	$	49,421,081	$	22,096,447		$	1,639,722		$	73,193,405
Net loss		—		—		(5,038	)		—			(5,038	)
Stock based compensation expense		—		47,415		—			—			47,415
Other comprehensive income		—		—		—			419,362			419,362
Net loss		—		—		(1,122,703	)		—			(1,122,703	)
Balance, September 30, 2019	$	36,155	$	49,421,081	$	21,861,202		$	1,526,925		$	72,845,363
Other comprehensive loss		—		—		—			(1,836,122	)		(1,836,122	)
Balance, March 31, 2020	$	36,155	$	49,468,496	$	20,973,744		$	(196,400	)	$	70,281,995

	Nine Months Ended September 30, 2019 (Unaudited)
	Three Months Ended March 31, 2019 (Unaudited)
	Common Stock		Additional Paid-in Capital		Retained Earnings			Accumulated Other Comprehensive Income (Loss)			Total Equity
Balance, January 1, 2019	$	—	$	15,882,835	$	22,335,398		$	(1,230,016	)	$	36,988,217
Issuance of common stock		36,155		33,~~538~~580,~~246~~925		—			—			33,~~574~~617,~~401~~080
Net loss		—		—		(474,196	)		—			(474,196	)
Net income		—		—		91,789			—			91,789
Other comprehensive income		—		—		—			21,~~756~~294,~~941~~862			21,~~756~~294,~~941~~862
Balance, September 30, 2019	$	36,155	$	49,421,081	$	21,861,202		$	1,526,925		$	72,845,363
Balance, March 31, 2019	$	36,155	$	49,463,760	$	22,427,187		$	64,846		$	71,991,948

	Three Months Ended September 30, 2018 (Unaudited Combined)
	Common Stock		Additional Paid-in Capital		Retained Earnings			Accumulated Other Comprehensive Income (Loss)			Total Equity
Balance, July 1, 2018	$	—	$	15,882,835	$	26,561,269		$	(1,387,779	)	$	41,056,325
Net loss		—		—		(473,400	)		—			(473,400	)
Other comprehensive loss		—		—		—			(127,759	)		(127,759	)
Balance, September 30, 2018	$	-	$	15,882,835	$	26,087,869		$	(1,515,538	)	$	40,455,166

	Nine Months Ended September 30, 2018 (Unaudited Combined)
	Common Stock		Additional Paid-in Capital		Retained Earnings			Accumulated Other Comprehensive Income (Loss)			Total Equity
Balance, January 1, 2018	$	—	$	15,882,835	$	26,319,019		$	1,448,639		$	43,650,493
Net loss		—		—		(1,619,045	)		—			(1,619,045	)
Other comprehensive loss		—		—		—			(1,576,282	)		(1,576,282	)
Reclassification of unrealized gain of equity securities		—		—		1,387,895			(1,387,895	)		—
Balance, September 30, 2018	$	—	$	15,882,835	$	26,087,869		$	(1,515,538	)	$	40,455,166

The accompanying notes are an integral part of these consolidated financial statements.

Positive Physicians Holdings, Inc.

Consolidated Statements of Cash Flows

	Nine Months Ended September 30,
	Three Months Ended March 31,
	2019			2018
	2020			2019
	(Unaudited)			(Unaudited ~~Combined~~)
Cash flows from operating activities:
Net loss	$	(474,196	)	$	(1,619,045	)
Net income (loss)	$	(1,122,703	)	$	91,789
Adjustments to reconcile net loss to net cash used in operating activities:
Adjustments to reconcile net income (loss) to net cash flows provided by (used in) operating activities:
Deferred income taxes		~~(109~~215,~~058~~432	)		7555,~~369~~658
Net realized loss (gain) on sales of investments		180,680			(97,827	)
Net realized loss on sales of investments		205,438			34,946
Unrealized gain on equity securities and other investments		(1,090,056	)		(150,916	)
Unrealized loss (gain) on equity securities and other investments		1,758,983			(886,597	)
Amortization of bond premiums		177,776			188,442
Amortization of fixed maturity premiums		70,877			55,536
Depreciation and amortization expense		~~753~~370,~~987~~378			8013,~~878~~234
Stock based compensation expense		47,415			—
Changes in operating assets and liabilities:
Accrued investment income		~~(23~~25,~~355~~006	)		~~(57~~17,~~716~~552	)
Premiums receivable		1180,~~884,701~~119			2698,~~360,638~~075
Reinsurance recoverable		(~~974~~779,~~823~~717	)		~~224~~(251,~~837~~805	)
Income taxes recoverable		(~~367~~660,908	)		~~(211,830~~367	)
Unearned ceded premiums		~~(753~~970,~~608~~259	)		(741,~~253~~206,884	)
Deferred acquisition costs		1(383,~~240,853~~976	)		~~454~~(704,~~281~~911	)
Prepaid management fee		~~(10,000,000~~—	)		—(10,000,000	)
Other assets		~~208~~22,~~822~~343			(~~125~~179,~~416~~554	)
Losses and loss adjustment expenses		(2745,~~438,399~~376	)		(~~736~~1,~~142~~771,221	)
Unearned premiums		(1,~~110~~817,~~204~~064	)		(1,~~353~~844,~~908~~138	)
Reinsurance payable		~~662~~(503,~~906~~521	)		~~(232~~1,~~065~~491,536	)
Accounts payable, accrued expenses, and other liabilities		(2,~~204~~830,~~788~~120	)		(21,~~625~~668,~~657~~079	)
Due to affiliates		~~(167,577~~—	)		(~~595~~81,~~986~~613	)
Net cash flows used in operating activities		(14,236,706	)		(4,496,316	)
Net cash flows provided by (used in) operating activities		147,745			(12,447,833	)
Cash flows from investing activities:
Proceeds from sales of bond securities		9,178,609			16,343,298
Proceeds from sales of fixed maturity securities		7,311,231			4,803,891
Proceeds from sales of equity securities and other investments		2203,~~175,620~~111			~~488~~173,~~072~~190
Purchases of bond securities		(13,919,951	)		(14,307,320	)
Purchases of fixed maturity securities		(6,923,432	)		(124,967	)
Purchases of equity securities		(~~599~~318,~~091~~315	)		(1214,~~209,922~~277	)
Net purchases of short-term investments		(1,342,919	)		(299,568	)
Net sales of short-term investments		526,458			174,792
Net cash flows (used in) provided by investing activities		(4,507,732	)		1,014,560
Net cash flows provided by investing activities		799,053			4,812,629
Cash flows from financing activities
Proceeds from issuance of common stock		~~33,574,401~~—			—33,617,080
Payments of notes payable		(4616,~~624~~004	)		(4415,~~247~~231	)
Net cash flows provided by (used in) financing activities		33,527,777			(44,247	)
Net cash flows (used in) provided by financing activities		(16,004	)		33,601,849
Net change in cash and cash equivalents		14930,~~783,339~~794			(325,~~526~~966,~~003~~645	)
Cash and cash equivalents, at beginning of period		320,~~903~~988,~~620~~081			83,~~196~~903,~~226~~620
Cash and cash equivalents, at end of period	$	1821,~~686~~918,~~959~~875		$	429,~~670~~870,~~223~~265
Cash paid during the period for interest	$	~~3,173~~595		$	51,~~550~~188

The accompanying notes are an integral part of these consolidated financial statements.

Positive Physicians Holdings, Inc.

Notes to Unaudited Consolidated Financial Statements

1.	Organization

The accompanying unaudited consolidated financial statements include the accounts of Positive Physicians Holdings, Inc. and its wholly owned subsidiary (collectively referred to as the “Company”). Positive Physicians Holdings, Inc. is a ~~newly formed~~ Pennsylvania domiciled holding company, which was incorporated on May 1, 2018 for the purpose of acquiring three Pennsylvania based reciprocal insurance exchanges: Positive Physicians Insurance Exchange (“PPIX”), Professional Casualty Association (“PCA”), and Physicians’ Insurance Program Exchange (“PIPE”). In connection with the completion of the Company’s initial public offering, PPIX, PCA, and PIPE converted from reciprocal insurance exchanges into stock insurance companies and were merged together to form Positive Physicians Insurance Company (“Positive Insurance Company”), a wholly- owned subsidiary of the Company. The Company’s initial public offering and its acquisition of Positive Insurance Company were completed on March 27, 2019. Prior to that time, the Company had minimal assets and liabilities and had not engaged in any operations. References to the Company or Positive Insurance Company financial information in this Quarterly Report prior to the conversion and merger date is to the financial information of PPIX, PCA, and PIPE on a combined basis. When used in this Quarterly Report, “we” and “our” mean PPIX, PCA, and PIPE prior to March 27, 2019, and Positive Insurance Company thereafter.

Positive Insurance Company

Positive Insurance Company writes medical malpractice insurance for healthcare providers practicing in Pennsylvania, New Jersey, Ohio, Delaware, Maryland, South Carolina, and Michigan. Diversus Management, ~~Inc.~~LLC (“Diversus Management”) manages and administers essentially all of the operations of Positive Insurance Company under the terms of a management agreement. Diversus Management is a wholly owned subsidiary of Diversus, Inc. (“Diversus”). Pursuant to the terms of the agreement, effective March 27, 2019, Diversus Management provides such administrative services to Positive Insurance Company in exchange for fees based upon a percentage of Positive Insurance Company’s gross written premiums, less return premiums. Diversus Management may also earn quarterly performance management fees based on Positive Insurance Company’s combined ratio and net earned premiums. Positive Insurance Company remains responsible for all underwriting decisions and the payment of all claims and claims related expenses incurred under policies issued by Positive Insurance Company and for all sales commissions paid to producers.

Products and Services

Positive Insurance Company underwrites medical professional liability coverage for physicians, their corporations, medical groups, clinics and allied healthcare providers. Medical professional liability insurance (“MPLI”) protects physicians and other health care providers against liabilities arising from the rendering of, or failure to render, professional medical services. We offer claims-made coverage, claims-made plus, and occurrence-based policies as well as tail coverage in Pennsylvania, New Jersey, Ohio, Delaware, Maryland, South Carolina, and Michigan. Our policies include coverage for the cost of defending claims. Claims-made policies provide coverage to the policyholder for claims reported during the period of coverage. We offer extended reporting endorsements, or tails, to cover claims reported after the policy expires. Occurrence-based policies provide coverage to the policyholders for all losses incurred during the policy coverage year regardless of when the claims are reported. Although we generate a majority of our premiums from individual and small group practices, we also insure several major physician groups.

The Company accounts for its medical professional liability insurance business as a single reporting segment line of business.

Option Agreement

Upon completion of the conversions of PPIX, PCA, and PIPE and the securities offering on March 27, 2019, the Company and Diversus entered into an option agreement whereby either party has the option to cause Diversus, subject to shareholder approval, to merge with and become a wholly owned subsidiary of the Company. Under the terms of the agreement, the option may be exercised by either the Company or Diversus at any time (1) during the period beginning 2 years after completion of the conversions of the exchanges and ending 54 months after the completion of the conversions, or (2) if earlier than 2 years after the completion of the conversions, then such date that the majority stockholder of the Company no longer has the right to appoint a majority of the board of directors of the Company. In connection with any merger, the common stock shareholders of Diversus will receive either cash, common stock shares of the Company, or some combination thereof for their shares of Diversus’ common stock. With respect to the preferred stock shares of Diversus, they will either be paid out in cash or converted into common stock shares of Diversus as if such preferred stock shares were converted into Diversus’ common stock shares immediately prior to the effective date of the merger.

2.	Basis of Presentation

The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three ~~and nine~~ months ended ~~September~~March 3031, ~~2019~~2020 are not necessarily indicative of the results that may be expected for the year ending December 31, ~~2019~~2020.

Our consolidated financial statements include our accounts and those of our wholly owned subsidiary. We have eliminated all inter-company accounts and transactions in consolidation.

~~The~~Positive ~~Company~~Physicians ~~was formed on May 1~~Holdings, ~~2018 and the financial statements of the Company for the period from May 1, 2018 through December 31, 2018 have been audited~~Inc. ~~The~~ ~~accompanying~~was ~~unaudited~~formed ~~financial statements for 2018 have been prepared~~ on aMay ~~combined basis and reflect our historical financial information and results of operations of PPIX, PCA, and PIPE as if the conversions and merger took place as of January~~ 1, 2018. Prior to the completion of the initial public offering, the Company, PPIX, PCA, and PIPE were under the common control of Diversus. Additionally, prior to March 27, 2019, the Company did not engage in substantive pre-combination activities, and accordingly, is not considered the acquirer of the net assets of Positive Insurance Company. The acquirer of these net assets is the majority stockholder of the Company. Accordingly, the accompanying unaudited financial statements do not reflect any adjustments to fair value as might have been determined had the Company accounted for the acquisition of Positive Insurance Company’s net assets as a business combination. The 2018 unaudited financial information is not necessarily indicative of the results of operations that would have been achieved if the conversions and merger had taken place at the beginning of 2018.

We recommend you read the interim consolidated financial statements we include in this Form 10-Q Report in conjunction with the financial statements and the notes to our financial statements contained in our Annual Report on Form 10-K for the year ended December 31, ~~2018~~2019.

3.	Summary of Significant Accounting Policies

Use of Estimates

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in these consolidated financial statements and notes. Actual results could differ from these estimates and such differences could be material. The Company’s principal estimates include the liability for losses and loss adjustment expenses, deferred acquisition costs, other-than-temporary impairments of investments, and valuation of deferred tax assets.

Cash and Cash Equivalents

The Company considers cash and cash equivalents to be cash on hand and depository bank accounts with original maturities of three months or less, are readily convertible to known amounts of cash, and present insignificant risk of changes in value due to changing interest rates.

Investments

Investments in fixed maturity securities are classified as available-for-sale and are stated at fair value. Unrealized holding gains and losses, net of related tax effects, on available-for-sale fixed maturity securities are recorded directly to accumulated other comprehensive income (loss). Investments in equity securities are stated at fair value and unrealized holding gains and losses are credited or charged to net income (loss) as incurred and are included in realized investment (losses) gains, net in the accompanying consolidated statements of operations.

WeRealized ~~have~~gains ~~ownership~~and ~~interests~~losses inon ~~limited~~sales ~~partnership~~of equity ~~hedge~~and ~~funds,~~fixed ~~which~~maturity securities are ~~reported~~recognized asinto ~~other~~income ~~investments~~based inupon the ~~accompanying~~specific ~~consolidated~~identification ~~balance sheets~~method. ~~The~~Interest ~~partnership~~and ~~interests~~dividends are ~~measured~~recognized ~~at fair value using the funds’ net asset values~~ as ~~a practical expedient~~earned. ~~Unrealized~~Short-term ~~holding~~investments ~~gains and losses on partnership interests~~ are ~~credited~~considered ~~or charged~~ to ~~net~~be ~~income~~short-term, ~~(loss)~~highly asliquid ~~incurred~~investments ~~and~~that are ~~included~~less inthan ~~realized~~one ~~investment~~year ~~(losses)~~in ~~gains,~~term ~~net~~to in the ~~accompanying~~dates ~~consolidated statements~~ of ~~operations. There~~maturity ~~are~~at nothe ~~unfunded~~purchase ~~commitments~~dates, ~~related~~and tothey ~~these~~present ~~investments. The~~insignificant ~~funds’~~risk ~~investment~~of ~~strategies~~changes ~~are short/long-term equities~~ in ~~financial~~value ~~institutions,~~due ~~long-term~~to ~~equity~~changing ~~securities,~~interest ~~and fixed maturity and equity securities in global opportunities~~rates.

Realized gains and losses on sales of equity and fixed maturity securities as well as other investments are recognized into income based upon the specific identification method. Interest and dividends are recognized as earned. Short-term investments are considered to be short-term, highly liquid investments that are less than one year in term to the dates of maturity at the purchase dates, and they present insignificant risk of changes in value due to changing interest rates.

The Company regularly evaluates all of its investments based on current economic conditions, credit loss experience, and other specific developments. If there is a decline in a security’s net realizable value that is other than temporary, it is considered as a realized loss and the cost basis in the security is reduced to its estimated fair value.

A fixed maturity security is considered to be other-than-temporarily impaired when the security’s fair value is less than its amortized cost basis and 1) we intend to sell the security, 2) it is more likely than not that we will be required to sell the security before recovery of the security’s amortized cost basis, or 3) we believe we will be unable to recover the entire amortized cost basis of the security (i.e., credit loss has occurred). Other-than-temporary-impairments (“OTTI”) of fixed maturity securities are separated into credit and noncredit-related amounts when there are credit-related losses associated with the impaired fixed maturity security for which management asserts that it does not have the intent to sell the security, and it is more likely than not that it will not be required to sell the security before recovery of its cost basis. The amount of the OTTI related to a credit loss is recognized in earnings, and the amount of the OTTI related to other factors is recorded in other comprehensive income (loss). A credit loss is determined by assessing whether the amortized cost basis of the security will be recovered, by comparing the present value of cash flows expected to be collected from the security, computed using original yield as the discount rate, to the amortized cost basis of the security. The shortfall of the present value of the cash flows expected to be collected in relation to the amortized cost basis is considered to be the “credit loss.”

Deferred Acquisition Costs

Certain direct acquisition costs consisting of commissions, premium taxes and certain other direct underwriting expenses that vary with and are primarily related to the successful production of business are deferred and amortized over the effective period of the related insurance policies as the underlying policy premiums are earned. The method followed in computing deferred acquisition costs limits the amount of deferred costs to their estimated realizable value, which gives effect to the premium to be earned, related investment income, losses and loss adjustment expenses, and certain other costs expected to be incurred as the premium is earned. Future changes in estimates, the most significant of which is expected losses and loss adjustment expenses, may require adjustments to deferred acquisition costs. If the estimation of net realizable value indicates that the deferred acquisition costs are not recoverable, then they would be written off.

Prepaid Management Fee

Prepaid management fee comprises costs incurred by the Company to execute a new management agreement with Diversus Management and is amortized on a straight-line basis over the seven-year useful life of the agreement.

Liability for Losses and Loss Adjustment Expenses

Liability for losses and loss adjustment expenses include an amount determined from individual case estimates and loss reports and an amount, based on prior experience, actuarial assumptions and management judgments for losses incurred but not reported. Such liabilities are necessarily based on assumptions and estimates, and while management believes the amount is adequate, the ultimate liability may be in excess of or less than the amounts provided. The methods for making such estimates for establishing the resulting liabilities are continually reviewed. Estimating the ultimate cost of future losses and loss adjustment expenses is an uncertain and complex process. This estimation process is based upon the assumption that past developments are an appropriate indicator of future events and involves a variety of actuarial techniques that analyze experience, trends, and other relevant factors. The uncertainties involved with the reserving process include internal factors, such as changes in claims handling procedure, as well as external factors, such as economic trends and changes in the concepts of legal liability and damage awards. Accordingly, final loss settlements may vary from the present estimates, particularly when those payments may not occur until well into the future. Adjustments to previously established reserves are reflected in the operating results of the period in which the adjustment is determined to be necessary. Such adjustments could possibly be significant, reflecting any variety of new and adverse or favorable trends.

We also offer extended reporting coverage at no additional charge in the event of disability, death or retirement after a policyholder reaches the age of 55 and has been a mature-claims policyholder with Positive Insurance Company for at least one year. An extended reporting endorsement policy reserve is required to assure that premiums are not earned prematurely. This reserve is actuarially determined and the balance is included in unearned premiums in the consolidated balance sheets.

Reinsurance

WeThe ~~cede~~Company cedes insurance risk to other insurance companies. This arrangement allows us to minimize the net loss potential arising from large risks. Reinsurance contracts do not relieve usthe Company of ~~our~~its obligation to its policyholders. Reinsurance premiums, losses, and loss adjustment expenses are accounted for on a basis consistent with those used in accounting for the original policies issued and the terms of the reinsurance contract.

Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, short-term investments, non-U.S. government bonds, premiums receivable, and balances recoverable from reinsurers. Non-U.S. government bonds are diversified, and no one investment accounts for greater than 5% of our invested assets. Cash and cash equivalents are deposited with financial institutions with balances that fluctuate in excess of federally insured limits. If the financial institutions were not to honor their contractual liability to us, we could incur losses. We are of the opinion that there is low risk because of the financial strength of the respective financial institutions. We are also subject to concentrations of credit risk through short-term money market investments. The credit risk related to short-term money market investments is minimized by our investing in money market funds or repurchase agreements, both secured by U.S. government securities.

No one insured accounted for over 10% of premiums receivable as of ~~September~~March 3031, ~~2019~~2020 and December 31, ~~2018~~2019 or gross written premium for the three ~~and nine~~ months ended ~~September~~March 3031, ~~2019~~2020 and ~~2018~~2019. We have reinsurance contracts with various reinsurers all of whom have A.M. Best ratings of A or better or have provided collateral to secure their obligations.

Revenue Recognition

Premiums are earned on a daily pro rata basis over the terms of the insurance policies. Unearned premium reserves are established to cover the unexpired portion of the policies in force less amounts ceded to reinsurers. For consideration received for policies with effective dates subsequent to the reporting period, the Company records an advance premium liability in lieu of written premium.

Premiums associated with tails are generally earned as written, except for the afore-mentioned extended reporting coverage in the event of disability, death or retirement. Other forms of tails, in which premiums are earned as written, include the following: 1) An insured who terminates a claims-made policy with their prior carrier, and who purchases tail coverage (extended reporting coverage) from their old carrier or obtains retroactive (prior-acts) coverage from a new carrier, or 2) Stand-alone tail coverage in which an insured is offered a tail policy by their prior carrier but seeks a competitive quote from a different carrier. Both types of tail coverage insure against claims reported after the end of the original policy period for incidents that occurred while that policy was in effect.

Comprehensive Income (Loss)

Certain changes in assets and liabilities, such as unrealized gains and losses on available-for-sale fixed maturity securities and unrealized losses related to factors other than credit on fixed maturity securities, are reported as a separate component in the equity section in the accompanying consolidated balance sheets. Such items, along with net income (loss), are components of comprehensive income (loss), and are reflected in the accompanying consolidated statements of comprehensive income (loss). Reclassifications of realized gains and losses on sales of investments out of accumulated other comprehensive income (loss) are recorded in realized investment (losses) gains, net in the accompanying consolidated statements of operations.

Income Taxes

The Company accounts for income taxes under the asset and liability approach, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in our consolidated financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the consolidated financial statements and the tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

The Company records net deferred tax assets to the extent it believes these assets will more likely than not be realized. In making such determination, we consider all available positive and negative evidence, including future reversal of existing taxable temporary differences, tax planning strategies, projected future taxable income, and recent financial operations.

Prior to March 27, 2019, PPIX, PCA, and PIPE filed separate federal income tax returns. The Company did not recognize any interest and penalties in the accompanying consolidated statements of operations for the three ~~and nine~~ months ended ~~September~~March 3031, ~~2019~~2020 and ~~the combined statements of operations for the three and nine months ended September 30, 2018~~2019. PPIX, PCA, and PIPE remain subject to examination by the Internal Revenue Service for tax years 2016 through 2018 and the short stub period in 2019. Beginning with the 2019 tax year, the Company will file a consolidated federal income tax return.

4.	Recent Accounting Pronouncements

As an emerging growth company, we have elected to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act. The following discussion includes effective dates for both public business entities and emerging growth companies, as well as whether specific guidance may be adopted early.

Recently Adopted Accounting Pronouncements

~~The~~In ~~Company~~February ~~adopted~~2016, the ~~provisions of~~ Financial Accounting Standards Board (“FASB”) ~~Accounting~~issued ~~Standards~~guidance ~~Update~~that ~~(“ASU”)~~requires ~~2016~~lessees to recognize leases, including operating leases, on the lessee’s balance sheet, unless a lease is considered a short-01term lease. This guidance also requires entities to make new judgments to identify leases. The guidance was effective for ~~the~~annual ~~year~~and ~~ended~~interim ~~December~~reporting 31periods beginning after December 15, 2018 and permitted early adoption. The Company’s adoption of this guidance on January 1, 2019 did not have a significant impact on our financial condition, results of operations or cash flows.

The amendments in this ASU:

• require, among other things, that equity investments be measured at fair value with changes in fair value recognized in net income,

• simplify the impairment assessment of equity investments without readily determinable fair values by requiring a qualitative assessment to identify impairment,

• eliminate the requirement for public business entities to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet,

• require public business entities to use the exit price notion when measuring the fair value of financial instruments for disclosure purposes,

• require an entity to present separately in other comprehensive income the portion of the total change in the fair value of the liability resulting from a change in the instrument-specific credit risk when the entity has elected to measure the liability at fair value in accordance with the fair value option for financial instruments,

• require separate presentation of financial assets and financial liabilities by measurement category and form of financial asset on the balance sheet or the accompanying notes to the consolidated financial statements, and

• clarify that an entity should evaluate the need for a valuation allowance on a deferred tax asset related to available-for-sale securities in combination with the entity’s other deferred tax assets.

With the adoption of ASU 2016-01, a cumulative effect of unrealized holding gains and losses on previously classified available-for-sale equity securities included in accumulated other comprehensive income at January 1, 2018 are to be reclassified to retained earnings. At January 1, 2018, unrealized holding gains in equity securities, net of tax effect, of $1,387,895 were reclassified from accumulated other comprehensive income to retained earnings for the year ended December 31, 2018.

Recently Issued Accounting Pronouncements

New accounting rules and disclosure requirements can impact the results and the comparability of the Company’s consolidated financial statements. The following recently issued accounting pronouncements are relevant to the Company’s consolidated financial statements:

In June 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments - Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments. The amendments in this Update require a new topic to be added (Topic 326) to the Accounting Standards Codification ("ASC") and removes the thresholds that entities apply to measure credit losses on financial instruments measured at amortized cost, such as loans, trade receivables, reinsurance recoverables, off-balance-sheet credit exposures, and held-to-maturity securities. Under current GAAP, entities generally recognize credit losses when it is probable that the loss has been incurred. The guidance under ASU 2016-13 will remove all current recognition thresholds and will require entities under the new current expected credit loss ("CECL") model to recognize an allowance for credit losses for the difference between the amortized cost basis of a financial instrument and the amount of amortized cost that an entity expects to collect over the instrument's contractual life. The new CECL model is based upon expected losses rather than incurred losses. Additionally, the credit loss recognition guidance for available-for-sale securities is amended and will require that credit losses on such debt securities should be recognized as an allowance for credit losses rather than a direct write-down of amortized cost balance. The ASU was effective for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. In November 2019, the FASB issued ASU 2019-10, Financial Instruments – Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842), which extended the effective date of adopting ASU 2016-13. Under ASU 2019-10, ASU 2016-13 will be effective for Public Business Entities that are SEC filers, excluding smaller reporting companies such as the Company, for fiscal years beginning after December 15, 2019 and interim periods within those fiscal years. For all other entities, including smaller reporting companies like the Company, ASU 2016-13 will be effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. For all entities, early adoption will continue to be permitted; that is, early adoption is allowed for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years (that is, effective January 1, 2019, for calendar year-end companies). The Company is currently a smaller reporting company, so the Company’s expected adoption date for ASU 2016-13 is January 1, 2023. At this time, we are evaluating the potential impact of ASU 2016-13 in the Company’s consolidated financial statements.

guidance under ASU 2016-13 will remove all current recognition thresholds and will require entities under the new current expected credit loss ("CECL") model to recognize an allowance for credit losses for the difference between the amortized cost basis of a financial instrument and the amount of amortized cost that an entity expects to collect over the instrument's contractual life. The new CECL model is based upon expected losses rather than incurred losses. Additionally, the credit loss recognition guidance for available-for-sale securities is amended and will require that credit losses on such debt securities should be recognized as an allowance for credit losses rather than a direct write-down of amortized cost balance. The ASU is effective for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. In July 2019, the FASB decided to add a project to its technical agenda to propose staggered effective dates for certain accounting standards, including ASU 2016-13. The FASB has proposed an approach that ASU 2016-13 will be effective for Public Business Entities that are SEC filers, excluding smaller reporting companies such as the Company, for fiscal years beginning after December 15, 2019 and interim periods within those fiscal years. For all other entities, including smaller reporting companies like the Company, ASU 2016-13 will be effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. For all entities, early adoption will continue to be permitted; that is, early adoption is allowed for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years (that is, effective January 1, 2019, for calendar-year-end companies). The new ASU for this project was approved by FASB in October 2019 and is expected to be issued in November 2019. The Company is currently a smaller reporting company, so once the ASU becomes effective, the Company’s expected adoption date for ASU 2016-13 would change from fiscal years beginning after December 15, 2019 to fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. At this time, we are evaluating the potential impact of ASU 2016-13 in the Company’s consolidated financial statements.

5.	Investments

WeThe ~~use~~Company uses fair value measurements to record fair value adjustments to certain assets to determine fair value disclosures. Fixed maturity available-for-sale securities and equity securities are recorded at fair value on a recurring basis. FASB ASC Topic 820 “Fair Value Measurements and Disclosures” establishes a fair value hierarchy that prioritizes the inputs to valuation methods used to measure fair value. The three levels of the fair value hierarchy under ASC Topic 820 are as follows:

Level 1:

Quoted (unadjusted) prices for identical assets in active markets.

Level 2: ~~Quoted~~Other ~~prices~~observable ~~for similar assets in active markets~~inputs, ~~quoted~~either ~~prices~~directly ~~for identical~~ or ~~similar assets in nonactive markets (few transactions~~indirectly, limited information, noncurrent prices, high variability over time, etc., inputs other than quoted prices that are observable for the asset (interest rates, yield curves, volatilities, default rates, etc., and inputs that are derived principally from or corroborated by other observable market data)).including:

•

Quoted prices for similar assets in active markets;

•

Quoted prices for identical or similar assets in nonactive markets (few transactions, limited information, noncurrent prices, high variability over time, etc.);

•

Inputs other than quoted prices that are observable for the asset (interest rates, yield curves, volatilities, default rates, etc.); and

•

Inputs that are derived principally from or corroborated by other observable market data.

Level 3:

Unobservable inputs that cannot be corroborated by observable market data.

Under ASC Topic 820, we base fair values of assets on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. It is our policy to maximize the use of observable inputs and minimize the use of unobservable inputs when developing fair value measurements, in accordance with the fair value hierarchy in FASB ASC Topic 820. Fair value measurements for assets where there exists limited or no observable market data and, therefore, are based primarily upon our or other third-party’s estimates, are often calculated based on the characteristics of the asset, the economic and competitive environment and other such factors. Management uses its best judgment in estimating the fair value of financial instruments; however, there are inherent weaknesses in any estimation technique. Therefore, for substantially all financial instruments, the fair value estimates herein are not necessarily indicative of the amounts we could have realized in a sales transaction on the dates indicated. The estimated fair value amounts have been measured as of their respective period end and have not been re-evaluated or updated for purposes of the consolidated financial statements subsequent to those respective dates. As such, the estimated fair values of these financial instruments subsequent to the respective reporting dates may be different than the amounts reported at each period-end. Additionally, changes in the underlying assumptions used, including discount rates and estimates of future cash flows, could significantly affect the results of current or future valuations.

We obtain one price for each security primarily from a third-party pricing service (“pricing service”), which generally uses quoted prices or other observable inputs for the determination of fair value. The pricing service normally derives the security prices through recently reported trades for identical or similar securities, making adjustments through the reporting date based upon available observable market information. For securities not actively traded, the pricing service may use quoted market prices of comparable instruments or discounted cash flow analyses, incorporating inputs that are currently observable in the markets for similar securities. Inputs that are often used in the valuation methodologies include, but are not limited to, non-binding broker quotes, benchmark yields, credit spreads, default rates, and prepayment speeds.

In instances in which the inputs used to measure fair value fall into different levels of the fair value hierarchy, the fair value measurement has been determined based on the lowest-level input that is significant to the fair value measurement in its entirety. Our assessment of the significance of a particular item to the fair value measurement in its entirety requires judgment, including the consideration of inputs specific to the asset or liability.

Amortized cost/cost, gross unrealized gains, gross unrealized losses, and fair value of fixed maturity securities by major security type for the results at March 31, 2020 and December 31, 2019 are as follows:

	Amortized Cost/Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
March 31, 2020
U.S. government	$	9,323,710	$	215,137	$	17,108	$	9,521,739
States, territories, and possessions		1,092,785		40,288		—		1,133,073
Subdivisions of states, territories, and possessions		12,375,653		313,337		13,297		12,675,693
Industrial and miscellaneous		67,258,447		974,929		1,761,894		66,471,482
Total fixed maturity securities	$	90,050,595	$	1,543,691	$	1,792,299	$	89,801,987

assessment of the significance of a particular item to the fair value measurement in its entirety requires judgment, including the consideration of inputs specific to the asset or liability.

	Amortized Cost/Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
December 31, 2019
U.S. government	$	10,689,829	$	100,223	$	38,490	$	10,751,562
States, territories, and possessions		1,096,638		46,385		—		1,143,023
Subdivisions of states, territories, and possessions		12,440,863		389,472		7,470		12,822,865
Industrial and miscellaneous		69,445,114		1,591,777		6,299		71,030,592
Total fixed maturity securities	$	93,672,444	$	2,127,857	$	52,259	$	95,748,042

~~Amortized~~The ~~cost/cost,~~table ~~gross~~below ~~unrealized~~sets ~~gains,~~forth ~~gross~~the ~~unrealized~~contractual ~~losses,~~maturity ~~and~~profile ~~fair~~of ~~value~~our ofinvestments in fixed maturity securities at March 31, 2020 and ~~equity~~December ~~securities~~31, by2019. Expected ~~major~~maturities ~~security~~could ~~type~~differ ~~for~~from ~~the~~contractual ~~results~~maturities atbecause ~~September~~borrowers ~~30,~~may ~~2019~~have ~~and~~the ~~December~~right 31to call or prepay obligations, ~~2018~~with ~~are~~or aswithout ~~follows:~~call or prepayment penalties.

	Amortized Cost/Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
	March 31, 2020				December 31, 2019
September 30, 2019
	Amortized Cost/Cost		Fair Value		Amortized Cost/Cost		Fair Value
U.S. government	$	12,798,909	$	118,141	$	50,783	$	12,866,267
Due in less than one year	$	10,817,722	$	10,827,211	$	8,570,607	$	8,584,991
States, territories, and possessions		1,100,524		49,258		—		1,149,782
Due after one year to five years		54,628,455		54,709,824		59,713,323		60,844,219
Subdivisions of states, territories, and possessions		12,531,299		358,227		11,231		12,878,295
Due after five years to ten years		23,822,755		23,422,426		24,656,702		25,539,400
Industrial and miscellaneous		64,875,153		1,490,372		21,167		66,344,358
Due after ten years		781,663		842,526		731,812		779,432
Total bonds		91,305,885		2,015,998		83,181		93,238,702
	$	90,050,595	$	89,801,987	$	93,672,444	$	95,748,042
Equity securities		6,579,604		1,137,479		365,437		7,351,646
	$	97,885,489	$	3,153,477	$	448,618	$	100,590,348

	Amortized Cost/Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
December 31, 2018
U.S. government	$	12,859,101	$	87,354	$	208,699	$	12,737,756
States, territories, and possessions		1,111,879		14,497		897		1,125,479
Subdivisions of states, territories, and possessions		13,230,690		105,965		44,591		13,292,064
Industrial and miscellaneous		59,561,984		14,030		1,524,644		58,051,370
Total bonds		86,763,654		221,846		1,778,831		85,206,669
Equity securities		7,568,810		524,526		826,242		7,267,094
	$	94,332,464	$	746,372	$	2,605,073	$	92,473,763

Realized gains and losses are determined using the specific identification method. During the three months ended March 31, 2020 and 2019, proceeds from maturities and sales and gross realized gains and losses on securities and other investments are as follows:

At September 30, 2019 and December 31, 2018, contractual maturities of investments in bond securities are as follows:

	Three Months Ended March 31,
	2020		2019
Proceeds	$	7,514,342	$	4,977,081
Gross gains		51,849		18,691
Gross losses		257,287		53,637

	September 30, 2019				December 31, 2018
	Amortized Cost/Cost		Fair Value		Amortized Cost/Cost		Fair Value
Due in less than one year	$	9,173,518	$	9,173,406	$	7,094,266	$	6,549,872
Due after one year to five years		58,418,818		59,389,696		50,676,297		47,892,580
Due after five years to ten years		22,981,731		23,875,216		27,617,956		29,361,896
Due after ten years		731,818		800,384		1,375,135		1,402,321
	$	91,305,885	$	93,238,702	$	86,763,654	$	85,206,669

The components of net realized investment (losses) gains for the three months ended March 31, 2020 and 2019 are as follows:

Realized gains and losses are determined using the specific identification method. During the three and nine months ended September 30, 2019 and 2018, proceeds from maturities and sales and gross realized gains and losses on securities and other investments are as follows:

	Three Months Ended March 31,
	2020			2019
Gain (loss) on sales of fixed maturity securities	$	39,043		$	(28,270	)
Loss on sales of equity securities and other investments		(244,481	)		(6,676	)
Total loss on sales of investments		(205,438	)		(34,946	)
Unrealized (loss) gain on equity securities and other investments		(1,758,983	)		886,597
Total net realized investment (losses) gains	$	(1,964,421	)	$	851,651

	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Proceeds	$	4,047,314	$	4,014,830	$	11,354,229	$	16,831,370
Gross gains		47,226		71,601		107,124		164,920
Gross losses		47,962		31,374		287,804		67,093

The components of net investment income for the three months ended March 31, 2020 and 2019 are as follows:

	Three Months Ended March 31,
	2020		2019
Fixed maturity securities	$	651,675	$	565,070
Cash and short-term investments		86,496		20,655
Equity securities		48,764		68,361
Other investments		7,125		9,233
		794,060		663,319
Less investment expenses		27,763		35,063
Net investment income	$	766,297	$	628,256

The ~~components~~following oftables ~~net~~show ~~realized~~fair ~~investment~~value (and gross unrealized losses) ~~gains~~of ~~for~~our ~~the~~fixed ~~three~~maturity ~~and~~investments ~~nine~~with ~~months~~unrealized ~~ended~~losses ~~September~~that 30are not deemed to be other-than temporarily impaired, ~~2019~~aggregated by investment category and ~~2018~~length ~~are~~of astime ~~follows~~that individual securities have been in a continuous unrealized loss position at March 31, 2020 and December 31, 2019:

	Three Months Ended September 30,					Nine Months Ended September 30,
	Less than 12 months					12 months or longer					Total
	2019			2018		2019			2018
Description of securities	Fair Value			Unrealized Losses		Fair Value			Unrealized Losses		Fair Value		Unrealized Losses
Gain (loss) on sales of bond securities	$	9,984		$	16,691	$	(18,264	)	$	13,226
March 31, 2020:
(Loss) gain on sales of equity securities and other investments		(10,720	)		23,536		(162,416	)		84,601
U.S. government	$	—		$	—	$	492,985		$	17,108	$	492,985	$	17,108
Total (loss) gain on sales of investments		(736	)		40,227		(180,680	)		97,827
States, territories, and possessions		—			—		—			—		—		—
Unrealized (loss) gain on equity securities and other investments		(115,157	)		185,266		1,090,056			150,916
Subdivisions of states, territories, and possessions		152,274			6,312		68,354			6,985		220,628		13,297
Total net realized investment (losses) gains	$	(115,893	)	$	225,493	$	909,376		$	248,743
Industrial and miscellaneous		28,285,031			1,761,894		—			—		28,285,031		1,761,894
Total fixed maturity securities	$	28,437,305		$	1,768,206	$	561,339		$	24,093	$	28,998,644	$	1,792,299

The components of net investment income for the three and nine months ended September 30, 2019 and 2018 are as follows:

	Less than 12 months				12 months or longer				Total
Description of securities	Fair Value		Unrealized Losses		Fair Value		Unrealized Losses		Fair Value		Unrealized Losses
December 31, 2019:
U.S. government	$	2,628,516	$	8,227	$	4,061,077	$	30,263	$	6,689,593	$	38,490
States, territories, and possessions		—		—		—		—		—		—
Subdivisions of states, territories, and possessions		—		—		93,000		7,470		93,000		7,470
Industrial and miscellaneous		4,773,607		5,934		350,922		365		5,124,529		6,299
Total fixed maturity securities	$	7,402,123	$	14,161	$	4,504,999	$	38,098	$	11,907,122	$	52,259

	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Bonds	$	621,987	$	592,550	$	1,748,218	$	1,726,507
Cash and short-term investments		108,572		19,196		286,156		48,790
Equity securities		60,975		83,365		202,468		231,878
Other investments		6,875		2,050		22,251		1,081
		798,409		697,161		2,259,093		2,008,256
Less investment expenses		28,402		33,584		94,583		93,646
Net investment income	$	770,007	$	663,577	$	2,164,510	$	1,914,610

The fair value and unrealized losses of our securities that were temporarily impaired as of September 30, 2019 and December 31, 2018 are as follows:

	Less than 12 months				12 months or longer				Total
Description of securities	Fair Value		Unrealized Losses		Fair Value		Unrealized Losses		Fair Value		Unrealized Losses
September 30, 2019:
U.S. government	$	3,424,282	$	9,856	$	5,336,033	$	40,927	$	8,760,315	$	50,783
Subdivisions of states, territories, and possessions		—		—		139,500		11,231		139,500		11,231
Industrial and miscellaneous		4,338,594		9,577		3,493,028		11,590		7,831,622		21,167
Total fixed maturities		7,762,876		19,433		8,968,561		63,748		16,731,437		83,181
Equity securities		834,110		48,272		698,627		317,165		1,532,737		365,437
Total temporarily impaired securities	$	8,596,986	$	67,705	$	9,667,188	$	380,913	$	18,264,174	$	448,618

	Less than 12 months				12 months or longer				Total
Description of securities	Fair Value		Unrealized Losses		Fair Value		Unrealized Losses		Fair Value		Unrealized Losses
December 31, 2018:
U.S. government	$	1,757,021	$	5,521	$	8,858,782	$	203,178	$	10,615,803	$	208,699
States, territories, and possessions		410,416		897		—		—		410,416		897
Subdivisions of states, territories, and possessions		3,138,650		11,729		1,993,170		32,862		5,131,820		44,591
Industrial and miscellaneous		28,187,416		563,317		25,787,215		961,327		53,974,631		1,524,644
Total fixed maturities		33,493,503		581,464		36,639,167		1,197,367		70,132,670		1,778,831
Equity securities		2,914,528		471,382		631,297		354,860		3,545,825		826,242
Total temporarily impaired securities	$	36,408,031	$	1,052,846	$	37,270,464	$	1,552,227	$	73,678,495	$	2,605,073

Fair values of interest rate sensitive instruments may be affected by increases and decreases in prevailing interest rates, which generally translate, respectively, into decreases and increases in fair values of fixed maturity investments. The fair values of interest rate sensitive instruments also may be affected by the credit worthiness of the issuer, prepayment options, relative values of other investments, the liquidity of the instrument, and other general market conditions.

We evaluated each security and took into account the severity and duration of the impairment, the current rating on the bond, and the outlook for the issuer according to independent analysts. We found that the declines in fair value are most likely attributable to increases in interest rates, and there is no evidence that the likelihood of not receiving all of the contractual cash flows as expected has changed. Our fixed maturity portfolio is managed by our investment committee in concert with an outside investment manager for investment grade bond investments. By agreement, the investment manager cannot sell any security without the consent of our investment committee if such sale will result in a net realized loss.

We monitor our investment portfolio and review securities that have experienced a decline in fair value below cost to evaluate whether the decline is other than temporary. When assessing whether the amortized cost basis of the security will be recovered, we compare the present value of the cash flows likely to be collected, based on an evaluation of all available information relevant to the collectability of the security, to the amortized cost basis of the security. The shortfall of the present value of the cash flows expected to be collected in relation to the amortized cost basis is referred to as the “credit loss.” If there is a credit loss, the impairment is considered to be other-than-temporary. If we identify that an other-than-temporary impairment loss has occurred, we then determine whether we intend to sell the security, or if it is more likely than not that we will be required to sell the security prior to recovering the amortized cost basis less any current-period credit losses. If we determine that we do not intend to sell, and it is more likely than not that we won’t be required to sell the security, then the amount of the impairment loss related to the credit loss will be recorded in earnings, and the remaining portion of the other-than-temporary impairment loss will be recognized in other comprehensive income (loss), net of tax. If we determine that we intend to sell the security, or that it is more likely than not that we will be required to sell the security prior to recovering its amortized cost basis less any current-period credit losses, then the full amount of the other-than-temporary impairment will be recognized in earnings.

For the three ~~and nine~~ months ended ~~September~~March 3031, ~~2019~~2020 and ~~2018~~2019, we determined that none of our fixed maturity securities were other-than-temporarily impaired. Adverse investment market conditions, or poor operating results of underlying investments, could result in impairment charges in the future.

~~The table below presents the level within the fair value hierarchy generally utilized by us to estimate the fair value of assets disclosed on a recurring basis at September 30, 2019:~~ 13

.	Total		Level 1		Level 2		Level 3
U.S. government	$	12,866,267	$	—	$	12,866,267	$	—
States, territories, and possessions		1,149,782		—		1,149,782		—
Subdivisions of states, territories and possessions		12,878,295		—		12,878,295		—
Industrial and miscellaneous		66,344,358		—		66,344,358		—
Total bonds		93,238,702		—		93,238,702		—
Equity securities		7,351,646		7,351,646		—		—
	$	100,590,348	$	7,351,646	$	93,238,702	$	—

The table below presents the level within the fair value hierarchy generally utilized by us to estimate the fair value of assets disclosed on a recurring basis at March 31, 2020:

The table below presents the level within the fair value hierarchy generally utilized by us to estimate the fair value of assets disclosed on a recurring basis at December 31, 2018:

.	Total		Level 1		Level 2		Level 3
U.S. government	$	9,521,739	$	—	$	9,521,739	$	—
States, territories, and possessions		1,133,073		—		1,133,073		—
Subdivisions of states, territories and possessions		12,675,693		—		12,675,693		—
Industrial and miscellaneous		66,471,482		—		66,471,482		—
Total fixed maturity securities		89,801,987		—		89,801,987		—
Equity securities		5,868,709		5,868,709		—		—
	$	95,670,696	$	5,868,709	$	89,801,987	$	—

	Total		Level 1		Level 2		Level 3
U.S. government	$	12,737,756	$	—	$	12,737,756	$	—
States, territories, and possessions		1,125,479		—		1,125,479		—
Subdivisions of states, territories and possessions		13,292,064		—		13,292,064		—
Industrial and miscellaneous		58,051,370		—		58,051,370		—
Total bonds		85,206,669		—		85,206,669		—
Equity securities		7,267,094		7,267,094		—		—
	$	92,473,763	$	7,267,094	$	85,206,669	$	—

The table below presents the level within the fair value hierarchy generally utilized by us to estimate the fair value of assets disclosed on a recurring basis at December 31, 2019:

At September 30, 2019 and December 31, 2018, we had ownership interests in limited partnership equity hedge funds. Our partnership interests are measured at fair value using the funds’ net asset values as a practical expedient and are excluded from the fair value hierarchy tables above. At September 30, 2019, the fair value and cost basis of these investments were $3,320,010 and $2,800,000, respectively. At December 31, 2018, the fair value and cost basis of these investments were $4,051,399 and $3,547,687, respectively. During the three and nine months ended September 30, 2019, we sold an investment in a limited partnership and recognized a realized gain of $36,714. There were no sales of limited partnerships during the same periods in 2018.

	Total		Level 1		Level 2		Level 3
U.S. government	$	10,751,562	$	—	$	10,751,562	$	—
States, territories, and possessions		1,143,023		—		1,143,023		—
Subdivisions of states, territories and possessions		12,822,865		—		12,822,865		—
Industrial and miscellaneous		71,030,592		—		71,030,592		—
Total fixed maturity securities		95,748,042		—		95,748,042		—
Equity securities		7,756,966		7,756,966		—		—
	$	103,505,008	$	7,756,966	$	95,748,042	$	—

6.	Deferred Acquisition Costs

The following table summarizes the ~~components~~movements ofin deferred acquisition costs for the three ~~and nine~~ months ended ~~September~~March 3031, ~~2019~~2020 and ~~2018~~2019:

Three Months Ended September 30,

Nine Months Ended September 30,

Three Months Ended March 31,

2019

2018

2019

2018

2020

2019

Balance, beginning of period

32,~~658~~584,~~457~~486

3,~~898~~985,~~747~~193

~~3,985,193~~

~~4,078,322~~

Amount capitalized during the period

1,~~310~~693,~~055~~778

12,~~936~~827,~~977~~265

~~5,070,465~~

~~6,239,715~~

Amount amortized during the period

21,~~224~~309,~~172~~802

2,~~211~~122,~~683~~354

~~6,311,318~~

~~6,693,996~~

Balance, end of period

2,~~744~~968,~~340~~462

34,~~624~~690,~~041~~104

~~2,744,340~~

~~3,624,041~~

7.	Reinsurance

~~Effective~~Under asthe ~~of March 27, 2019, Positive Insurance~~ Company’s ~~entered~~current ~~into a new policy~~ reinsurance agreement~~. Under the new agreement~~, we retain a portion of our exposure and pay to the reinsurers a portion of the premiums received on all policies reinsured. Insurance policies written by us are reinsured with other insurance companies principally to:

•

reduce net liability on individual risks and clash occurrences;

•

mitigate the effect of individual loss occurrences;

•

cover us against losses in excess of policy limits and extra contractual obligation claims;

•

stabilize underwriting results; and

•

increase our underwriting capacity.

Under Pennsylvania law, each insured must maintain MPLI of at least $1,000,000 for each claim and $3,000,000 of annual aggregate coverage. We provide primary insurance coverage up to $500,000 per claim and $1,500,000 of annual aggregate coverage. The Pennsylvania Medical Care Availability and Reduction of Error (“MCARE”) Fund provides coverage for any losses above $500,000 per claim up to $1,000,000. In cases where coverage under the Pennsylvania MCARE Fund does not apply, the primary insurance provides coverage up to $1,000,000 per claim and $3,000,000 of annual aggregate coverage. We retain the first $300,000 in loss on all Pennsylvania claims and reinsurance covers the excess up to $1,000,000 that is not covered by the Pennsylvania MCARE Fund. We cede to reinsurers any Pennsylvania claims in excess of $1,000,000.

Other states in which we write insurance require doctors to maintain certain minimum coverage and provide a fund that provides coverage for losses above a certain amount, but some states do not prescribe insurance requirements for doctors.

We offer primary coverage up to $1,000,000 for each claim and $3,000,000 of annual aggregate coverage in Delaware, Maryland, Michigan, Ohio, New Jersey, and South Carolina. We retain the first $300,000 in loss for claims from these states, and reinsurance covers the excess up to $1,000,000. If an insured in New Jersey requests, additional coverage of $1,000,000, each claim, each insured, each policy can be provided and is fully ceded to the reinsurer up to a maximum aggregate liability of $2,000,000 to the reinsurer per the term of the reinsurance agreement. In South Carolina and Michigan, the insured can elect policy limits of $200,000 per claim and, on these claims, we retain the first $100,000 and the reinsurer covers the next $100,000.

We also purchase additional reinsurance coverage for clash, losses in excess of policy limits and extra contractual obligation claims.

Our premiums under the ~~new~~current reinsurance agreement are based on a percentage of our earned premiums during the term of the agreement. The agreement ~~terminates~~was renewed on April 1, 2020.

Reinsurance does not legally discharge the insurance company issuing the policy from primary liability for the full amount due under the reinsured policies. A primary factor in the selection of reinsurers from whom we purchase reinsurance is their financial strength. Our reinsurance arrangements are generally renegotiated annually. The insolvency or inability of any reinsurer to meet its obligations to us could have a material adverse effect on our results of operations or financial condition. Our reinsurance providers, the majority of whom are longstanding partners that understand our business, are all carefully selected with the help of our reinsurance broker. We monitor the solvency of reinsurers through regular review of their financial statements and, if available, their A.M. Best ratings. ~~Hanover~~Hannover Re, our current reinsurance partner, has ~~at least~~ an “A+ (Superior)” rating from A.M. Best. According to A.M. Best, companies with a rating of “A” or better “have an excellent ability to meet their ongoing obligations to policyholders.”

We generally do not assume risks from other insurance companies. However, we could be required by statute to participate in guaranty funds, which are formed to pay claims on policies issued by insolvent property and casualty insurers domiciled in certain states, such as Pennsylvania. This participation, where applicable, requires us to pay an annual assessment based on our premiums written and determined on a market share basis. As of March 31, 2020, our participation was not material.

The effect of reinsurance on premiums written, amounts earned, and losses incurred for the three months ended March 31, 2020 and 2019 is as follows:

	Three Months Ended March 31,
	2020		2019
Premiums written:
Direct	$	7,718,512	$	8,197,517
Ceded		246,479		1,952,477
Premiums written, net of reinsurance	$	7,472,033	$	6,245,040
Premiums earned:
Direct	$	5,901,448	$	6,353,380
Ceded		1,216,738		862,173
Premiums earned, net of reinsurance	$	4,684,710	$	5,491,207
Losses and loss adjustment expenses incurred:
Direct	$	3,965,773	$	3,911,189
Ceded		780,170		589,513
Losses and loss adjustment expenses incurred, net of reinsurance	$	3,185,603	$	3,321,676

We generally do not assume risks from other insurance companies. However, we could be required by statute to participate in guaranty funds, which are formed to pay claims on policies issued by insolvent property and casualty insurers domiciled in certain states, such as Pennsylvania. This participation, where applicable, requires us to pay an annual assessment based on our premiums written and determined on a market share basis. As of September 30, 2019, our participation was not material.

On October 9, 2018, Positive Physicians Captive Insurance Company (“PPCIC”), a sponsored captive insurance company, was incorporated in the State of New Jersey and is a wholly owned subsidiary of Positive Insurance Company. PPCIC was licensed under the New Jersey Captive Insurance Act on October 16, 2018. PPCIC has one protected unincorporated cell, Keystone Captive Group (“Keystone”). Keystone is owned by an insured of Positive Insurance Company. Effective October 16, 2018, the Company entered into a reinsurance agreement with Keystone.

The effect of reinsurance on premiums written, amounts earned, and losses incurred for the three and nine months ended September 30, 2019 and 2018 is as follows:

	Three Months Ended September 30,					Nine Months Ended September 30,
	2019		2018			2019		2018
Premiums written:
Direct	$	7,307,405	$	5,644,259		$	19,288,247	$	17,604,128
Ceded		742,219		379,552			3,342,950		2,546,976
Premiums written, net of reinsurance	$	6,565,186	$	5,264,707		$	15,945,297	$	15,057,152
Premiums earned:
Direct	$	7,969,537	$	6,222,970		$	20,398,452	$	18,958,037
Ceded		979,627		929,314			2,589,341		2,472,724
Premiums earned, net of reinsurance	$	6,989,910	$	5,293,656		$	17,809,111	$	16,485,313
Losses and loss adjustment expenses incurred:
Direct	$	4,445,603	$	3,565,411		$	14,721,869	$	13,370,097
Ceded		324,547		(198,791	)		3,011,697		1,617,811
Losses and loss adjustment expenses incurred, net of reinsurance	$	4,121,056	$	3,764,202		$	11,710,172	$	11,752,286

8.	Losses and Loss Adjustment Expenses

The following table provides a reconciliation of our beginning and ending unpaid loss and loss adjustment expense (“LAE”) reserve balances for the ~~nine~~three months ended ~~September~~March 3031, ~~2019~~2020 and ~~2018~~2019.

	2019			2018
	2020			2019
Balance at January 1	$	6863,~~392~~607,~~333~~975		$	68,~~374~~392,~~554~~333
Less: Reinsurance recoverable on liability for losses and loss adjustment expenses		7,~~956~~850,~~043~~409			87,~~585~~956,~~851~~043
Add: Reinsurance recoverable on claims paid		5335,~~791~~274			15,~~196,573~~791
Net liability at January 1		6056,~~442~~092,~~081~~840			60,~~985~~442,~~276~~081
Losses and loss adjustment expenses incurred, net:
Current period		113,~~731~~185,~~068~~603			13,~~980~~321,~~286~~676
Prior periods		~~(20,896~~—	)		~~9,772,000~~—
Total incurred losses and loss adjustment expenses		113,~~710~~185,~~172~~603			113,~~752~~321,~~286~~676
Less losses and loss adjustment expenses paid, net:
Current period		~~203~~57,~~693~~756			~~437~~79,~~000~~592
Prior periods		142,~~144~~801,~~675~~374			125,~~921~~013,~~119~~009
Total losses and loss adjustment expenses paid		142,~~348~~859,~~368~~130			135,~~358~~092,~~119~~601
Net liability for losses and loss adjustment expenses, at September 30		57,803,885			59,379,443
Net liability for losses and loss adjustment expenses, at March 31		56,419,313			58,671,156
Add: Reinsurance recoverable on liability for losses and loss adjustment expenses		8,~~930~~630,~~866~~126			8,~~361~~207,~~014~~848
Less: Reinsurance recoverable on claims paid		~~780~~696,~~817~~088			~~102~~257,~~045~~892
Liability for losses and loss adjustment expenses, at September 30	$	65,953,934		$	67,638,412
Liability for losses and loss adjustment expenses, at March 31	$	64,353,351		$	66,621,112

The liability for losses and LAE at ~~September~~March 3031, ~~2019~~2020 and ~~2018~~2019 was $6564,~~953~~353,~~934~~351 and $6766,~~638~~621,~~412~~112, respectively. For the ~~nine~~three months ended ~~September~~March 3031, ~~2019~~2020 and ~~2018~~2019, $142,~~144~~801,~~675~~374 and $125,~~921~~013,~~119~~009, respectively, has been paid for incurred claims attributable to insured events of prior years. Original estimates are increased or decreased, as additional information becomes known regarding individual claims. The Company recorded modest favorable development on its prior period reserves for the nine months ended September 30, 2019, and during the nine months ended September 30, 2018, the Company experienced unfavorable development of $9,772,000 primarily related to significant reserve strengthening in the 2014 and 2015 accident years for both claims-made and occurrence policies. This increase was due to a greater amount of incurred losses and LAE than originally estimated.

Positive Insurance Company uses a combination of the Actual versus Expected Method, Bornhuetter-Ferguson Method, Expected Loss Ratio Method, Frequency/Severity Method, and the Incurred Loss Development Method in order to estimate its liability for losses and LAE. Beginning in the third quarter of 2019, the Company changed its approach by aggregating its data, previously under PPIX, PCA, and PIPE, and performing a single loss reserve analysis, as opposed to three separate loss reserve analyses. The Company also used development patterns strictly based on former PPIX experience. Management does not believe that the effects of these changes had a material impact on the Company’s estimates. There were no ~~other~~ significant changes in the methodologies and assumptions used to develop the liabilities for losses and LAE during the ~~nine~~three months ended ~~September~~March 3031, ~~2019~~2020.

9. ~~Note~~Income ~~Payable~~Taxes

OnAt ~~December~~March 1231, ~~2014,~~2020 ~~PPIX~~and ~~entered~~December ~~into~~31, ~~a loan agreement with a financial institution with proceeds totaling $300~~2019,~~000~~ ~~to finance~~ the ~~development~~Company ofhad ano ~~new~~unrecognized ~~policy~~tax ~~system. The~~benefits, ~~loan~~no isaccrued ~~secured~~interest byand ~~the~~penalties, ~~equipment~~and ~~purchased~~no ~~with~~significant ~~the~~uncertain ~~proceeds~~tax ~~received~~positions. ~~The~~No ~~loan is being repaid on a monthly basis from January 2016 through December 2020 with~~ interest ~~calculated on the unpaid principal balance at a rate of 4% per annum. At September 30, 2019~~ and ~~December~~penalties ~~31,~~were ~~2018,~~recognized ~~the~~during ~~balance of~~ the ~~note~~three ~~payable~~months ~~was~~ended ~~$80,703~~March ~~and $127~~31,~~327,~~ ~~respectively,~~2020 and ~~PPIX remains compliant with all loan covenants~~2019.

At March 31, 2020 and December 31, 2019, the Company had unused net operating loss (“NOL”) carryforwards of $779,554 and $3,600,298, respectively, which will begin to expire in 2038, if unused. The Company’s remaining unused NOLs that were generated prior to the conversions and merger in 2019 are subject to limitations under Section 382 of the Internal Revenue Code and are limited in the amount that can be utilized in any one year. The Company’s NOL balance at March 31, 2020 also includes taxable losses that were generated by the holding company in 2020.

On March 27, 2020, President Trump signed the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) into law. The CARES Act includes certain income tax-related law changes that have a material effect on the Company’s deferred income taxes. The most significant effect on the Company’s deferred income taxes is due to changes in the federal net operating loss carryback provisions which allow the Company to carryback NOLs originating in 2018 and 2019 to prior tax years with corporate income tax rates of 34% (as opposed to forward to future tax years with corporate income tax rates of 21%). As a result of this legislation, during the first quarter of 2020, the Company significantly reduced its NOL balance by $3,090,478, or $649,000 tax-effected, and recorded additional federal income tax refunds of $1,119,633.

In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all the Company’s deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities (including the impact of available carryback and carryforward periods), tax planning strategies, and projected future taxable income in making this assessment. At March 31, 2020 and December 31, 2019, management determined that it was more likely than not that all of the deferred tax assets will be realized by the Company in future years. Accordingly, the Company did not record a valuation allowance against its deferred tax assets at March 31, 2020 and December 31, 2019.

10.	Agreements with Diversus

Positive Insurance Company has a management agreement with Diversus Management, whereby Diversus Management provides administrative services to Positive Insurance Company in exchange for fees based on a percentage of Positive Insurance Company’s gross written premium, less return premium. Under the current agreement, which became effective March 27, 2019, Diversus Management earns management fees at 12%. Diversus Management may also earn quarterly performance management fees based on Positive Insurance Company’s combined ratio and net earned premiums. No quarterly performance fees were payable under the terms of the agreement at March 31, 2020.

Management fees are recorded in other underwriting expenses in the consolidated statements of operations. The Company incurred management fees for the respective periods as follows:

Three Months Ended

March 31,

2020

2019

Management fees

1,319,411

2,049,380

In connection with the execution of the existing management agreement with Diversus Management, the Company paid Diversus $10,000,000 to execute the agreement. Such payment is presented as prepaid management fee in the accompanying consolidated balance sheets and is amortized on a straight-line basis over a period of seven years. For the three months ended March 31, 2020, the Company incurred amortization expense of $357,143, which is recorded in other underwriting expenses in the consolidated statement of operations and included as part of the current year amount disclosed in the table above.

Positive Insurance Company has contracts with Gateway Risk Services, LLC and Andrews Outsource Solutions LLC, both of which are wholly owned subsidiaries of Diversus, under which those companies provide claims processing and risk management services. Fees incurred by Positive Insurance Company under these contracts are recorded in other underwriting expenses in the consolidated statements of operations as follows:

Three Months Ended

March 31,

2020

2019

Claims processing and risk management services

392,575

399,375

Additionally, the former attorney-in-fact of PCA earned commissions related to our gross written premium and other accounts. Beginning March 27, 2019, these commissions were paid to Specialty Insurance Agency, LLC, a wholly owned subsidiary of Diversus. These commissions are recorded in other underwriting expenses in the consolidated statements of operations. Positive Insurance Company incurred related commission expenses for the respective periods as follows:

Three Months Ended

March 31,

2020

2019

Commissions

62,073

77,850

The Company and Diversus entered into a loan agreement dated March 27, 2019 to provide a $6,000,000 credit facility to Diversus for working capital purposes. At March 31, 2020, there was no outstanding balance on the credit facility. The Company terminated the loan agreement on May 19, 2020.

1011. ~~Income~~Common ~~Taxes~~Stock

AtThe ~~September~~Company ~~30,~~is ~~2019~~authorized ~~and~~to ~~December~~issue 3110, ~~2018~~000,000 ~~the~~shares ~~Company~~of ~~had~~$0.01 nopar ~~unrecognized~~value ~~tax~~common ~~benefits,~~stock. In noconnection ~~accrued~~with ~~interest~~the ~~and~~completion ~~penalties,~~of ~~and~~the noinitial ~~significant~~public ~~uncertain~~offering ~~tax~~on ~~positions. No~~March ~~interest~~27, ~~and~~2019, ~~penalties~~3,615,500 ~~were~~shares ~~recognized~~of ~~during~~ the ~~periods~~Company’s ~~ended~~common ~~September~~stock ~~30,~~were ~~2019~~issued. ~~and~~At ~~December~~March 31, ~~2018~~2020, 3,615,500 shares of common stock remain issued and outstanding.

AtOn September 3027, 2019, ~~and~~the ~~December~~Company ~~31,~~granted ~~2018,~~its ~~the~~Chief ~~Company~~Executive ~~had~~Officer ~~unused~~options ~~net~~to ~~operating~~purchase ~~loss~~216,930 ~~(“NOL”)~~shares ~~carryforwards~~of common stock at an exercise price of $~~4,672,985 and~~12.01 ~~$3,865,253,~~per ~~respectively~~share, which ~~will~~was ~~begin~~the toclosing ~~expire~~sale inprice ~~2038,~~of ifthe ~~unused. At~~Company’s ~~September~~common ~~30,~~stock ~~2019~~on ~~and~~the ~~December~~date 31the options were granted. Of the total options, ~~2018~~108,465 ~~the~~shares ~~Company~~will ~~had~~vest ~~capital~~in ~~loss~~equal ~~carryforwards~~monthly ofinstallments ~~$345,246~~ over a three-and-one-half ~~$164~~year period following September 27,~~566~~ 2019, ~~respectively. At~~and the ~~time~~remaining of108,465 ~~the~~shares ~~conversion~~will ~~and~~vest ~~merger,~~upon the ~~Company~~achievement ~~had~~by ~~unused~~the ~~NOLs~~Company of ~~$5,310,679,~~certain ~~which~~milestones. All ~~are~~vested ~~subject~~option toshares ~~limitations~~shall ~~under~~be ~~Section~~exercisable ~~382~~for ofeight years from the ~~Internal~~date ~~Revenue~~of ~~Code~~vesting. The ~~and~~stock-based ~~are~~compensation ~~limited~~expense inrecorded by the ~~amount~~Company ~~that~~during ~~can~~the befirst ~~utilized~~quarter inof ~~any~~2020 ~~one~~was ~~year~~$47,415.

InThe ~~assessing~~holding ~~the~~company ~~realization~~has ofcash ~~deferred~~and ~~tax~~other liquid assets, ~~management~~aggregating ~~considers~~$16,786,967 ~~whether~~at itMarch is31, ~~more~~2020. The ~~likely~~holding ~~than not that some portion or all the Company~~company’s ~~deferred~~principal ~~tax~~source ~~assets~~of ~~will~~future ~~not~~liquidity will be ~~realized. The~~dividend ~~ultimate~~payments ~~realization~~from ofPositive ~~deferred~~Insurance ~~tax~~Company, ~~assets~~which is ~~dependent~~restricted ~~upon~~by the ~~generation~~insurance oflaws ~~future~~and ~~taxable~~regulations ~~income~~of ~~during~~ the ~~periods~~Commonwealth ~~in which those temporary differences become deductible. Management considers the scheduled reversal~~ of ~~deferred~~Pennsylvania ~~tax~~as ~~liabilities~~to ~~(including~~ the ~~impact~~amount of ~~carryback~~dividends ~~and~~or ~~carryforward~~other ~~periods),~~distributions ~~tax planning strategies, and projected future taxable income in making this assessment. At September 30, 2019 and December 31, 2018, management determined that~~ it ~~was~~may ~~more~~pay ~~likely~~to ~~than not that all~~ the ~~deferred tax assets will be realized by the~~ Company ~~in future years~~. ~~Accordingly, the Company did not record a valuation allowance against its deferred tax assets at September 30, 2019 and December 31, 2018.~~

11. Related Party Transactions

Positive Insurance Company is managed by Diversus Management. Prior to March 27, 2019, Diversus Management, through former attorneys-in-fact of PPIX, PCA, and PIPE, earned management fees at 25% of gross written premiums of the exchanges. Concurrrent with the acquisition of PPIX, PCA, and PIPE and the initial public offering on March 27, 2019, Positive Insurance Company and Diversus Management entered into a new management agreement, effective March 27, 2019, whereby Diversus Management provides administrative services to Positive Insurance Company in exchange for fees based on a percentage of Positive Insurance Company’s gross written premium, less return premium. Under the new agreement, Diversus Management earns management fees at 12%. Diversus Management may also earn quarterly performance management fees based on Positive Insurance Company’s combined ratio and net earned premiums.

Management fees are recorded in other underwriting expenses in the consolidated statements of operations. Positive Insurance Company incurred management fees for the respective periods, as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Management fees	$	879,615	$	1,411,065	$	3,459,174	$	4,401,032

In connection with the execution of the new management agreement with Diversus Management, the Company paid Diversus $10,000,000 to execute the agreement. Such payment is presented as “Prepaid management fee” in the accompany consolidated balance sheet at September 30, 2019 and is amortized on a straight-line basis over a period of seven years. For the three and nine months ended September 30, 2019, the Company incurred amortization expense of $357,143 and $714,286, respectively.

	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Claims processing and risk management services	$	416,775	$	384,875	$	1,225,025	$	1,196,625

	Three Months Ended September 30,					Nine Months Ended September 30,
	2019			2018		2019		2018
Commissions	$	(1,027	)	$	38,076	$	85,245	$	154,546

The Company and Diversus entered into a loan agreement dated March 29, 2019 to provide a $6,000,000 credit facility to Diversus for working capital purposes. Diversus may borrow in one or more advances up to $5,500,000 under a term loan and up to $500,000 under a revolving loan. Outstanding borrowings under the credit facility will bear interest at 8%, will be unsecured, and will be subordinate to the existing senior debt and other commercial loan obligations of Diversus. The loan is convertible into common stock shares of Diversus at a price of $1 per share at the option of the Company. At September 30, 2019, there was no outstanding balance on the credit facility.

12. Common Stock

The Company is authorized to issue 10,000,000 shares of $0.01 par value common stock. At December 31, 2018, there were no shares of common stock issued and outstanding. In connection with the completion of the initial public offering on March 27, 2019, 3,615,500 shares of the Company’s common stock were issued.

On September 27, 2019, the Company granted its Chief Executive Officer options to purchase 216,930 shares of common stock at an exercise price of $12.01 per share, which was the closing sale price of the Company’s common stock on the date the options were granted. Of the total options, 108,465 shares will vest in equal monthly installments over a three-and-one-half year period following September 27, 2019, and the remaining 108,465 shares will vest upon the achievement by the Company of certain milestones. All vested option shares shall be exercisable for eight years from the date of vesting. The stock-based compensation expense incurred by the Company during the three and nine months ended September 30, 2019 was not significant.

The Company’s principal source of liquidity will be dividend payments from Positive Insurance Company, which is restricted by the insurance laws and regulations of the Commonwealth of Pennsylvania as to the amount of dividends or other distributions it may pay to the Company.

An order by the Pennsylvania Insurance Department approving the conversions of PPIX, PCA, and PIPE prohibits the declaration or payment of any dividend, return of capital, or other distribution by the Company to Insurance Capital Group, LLC and Enstar Holdings (US) LLC, the two principal stockholders of the Company, or any other shareholder without the prior approval of the Pennsylvania Insurance Department, for a period of three years following the effective date of the conversions. Additionally, by the order of the Pennsylvania Insurance Department, Positive Insurance Company cannot pay a dividend to the Company for a period of three years following the effective date of the conversions without the approval of the Pennsylvania Insurance Department.

Prior to its payment of any dividend, Positive Insurance Company will be required to provide notice of the dividend to the Pennsylvania Insurance Department. This notice must be provided to the Pennsylvania Insurance Department 30 days prior to the payment of an extraordinary dividend and 10 days prior to the payment of an ordinary dividend. The Pennsylvania Insurance Department has the power to limit or prohibit dividends if Positive Insurance Company is in violation of any law or regulation.

1918

1312. Earnings Per Share

As discussed in Note 1, the conversions of PPIX, PCA, and PIPE to stock insurance companies and the simultaneous acquisition of these companies resulted in the issuance of the Company’s common stock as of March 27, 2019. The basic weighted average number of common shares outstanding was 3,615,500 for the three ~~and nine~~ months ended ~~September~~March 3031, ~~2019~~2020. For the period prior to the date of the conversions, the net common shares issued in the initial public offering were assumed to be outstanding since January 1, 2019.

The following table presents a reconciliation of the numerators and denominators that were used in the basic and diluted per share computations for the Company’s common stock:

	Three Months Ended September 30,					Nine Months Ended September 30,
	Three Months Ended March 31,
	2019			2018		2019			2018
	2020			2019
Basic earnings per common share:
Numerator:
Net loss	$	(5,038	)	N/A		$	(474,196	)	N/A
Net income (loss)	$	(1,122,703	)	$	91,789
Denominator:
Weighted average shares outstanding		3,615,500		~~N/A~~	3,615,500		~~3,615,500~~		~~N/A~~
Basic earnings per common share	$	(0.0031	)	~~N/A~~$	0.03	$	~~(0.13~~	)	~~N/A~~
Diluted earnings per common share:
Numerator:
Net income (loss)	$	(1,122,703	)	$	91,789
Denominator:
Weighted average shares outstanding - basic		3,615,500			3,615,500
Add: vested stock options		15,495			—
Number of shares used in diluted computation		3,630,995			3,615,500
Diluted earnings per common share	$	(0.31	)	$	0.03

2013. COVID-19

The Company’s operations and business have experienced disruptions due to the conditions surrounding the COVID-19 pandemic spreading throughout the United States. These disruptions include, but are not limited to, office closures and difficulties in maintaining operational continuance during remote operations required by illness, social quarantining, and work from home orders currently in force. The Company’s management has devoted substantial time and attention to assessing the potential impact of COVID-19 and those events on the Company’s operations and financial position and developing operational and financial plans to address those matters.

As a result of the COVID-19 pandemic, the Company anticipates that premiums will decrease due to policy endorsements associated with doctors electing to work part time, take a leave of absence or retire. In addition, our insureds may elect to temporarily change their areas of practice and/or specialties. For example, a doctor may choose to drop from orthopedic surgery to office-only status due to the lack of elective surgeries. The Company has received notification for such requests from our policyholders which will go into effect on June 30, 2020 and necessary reimbursements or credits against future payments will be applied.

In terms of collections, prior to the pandemic, the Company’s policy was to cancel any insurance policies for which premiums had not been received within 60 days subsequent to policy effective date, with notice of intent to cancel sent to the insured after 30 days post-inception date, or post-payment due date. As a result of COVID-19, the Company has updated this policy and suspended cancellations of insurance contracts resulting from non-payment of premium and deferred payments until June 30, 2020 for invoices due after April 1, 2020.

With respect to claims, Positive Insurance Company’s policyholder base mainly consists of physicians, their corporations and medical groups. During the COVID-19 pandemic, on-site visits to doctors have declined and been replaced by an increase in telehealth/virtual office visits. Since the COVID-19 pandemic resulted in government-issued work from home orders, the Company has seen the number of new claims reported begin to decrease.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion is intended to provide a more comprehensive review of ~~the~~Positive ~~Company~~Physicians Holdings, Inc. (“PPHI”) and its wholly owned subsidiary’s (collectively referred to as the “Company,” which also may be referred to as “we” or “us”) operating results and financial condition than can be obtained from reading the Financial Statements alone. The discussion should be read in conjunction with the Unaudited Consolidated Financial Statements and the notes thereto included in “Part I. Item 1. Financial Statements” of the Company. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q constitutes forward-looking information that involves risk and uncertainties. We also recommend you read Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended December 31, ~~2018~~2019.

OVERVIEW

Positive Physicians Holdings, Inc. ~~(the “Company”)~~ is a ~~newly formed~~ Pennsylvania domiciled holding company, which was incorporated on May 1, 2018 for the purpose of acquiring three Pennsylvania based reciprocal insurance exchanges: Positive Physicians Insurance Exchange (“PPIX”), Professional Casualty Association (“PCA”), and Physicians’ Insurance Program Exchange (“PIPE”). In connection with the completion of ~~the Company~~PPHI’s initial public offering, PPIX, PCA, and PIPE converted from reciprocal insurance exchanges into stock insurance companies.

As part of the conversions, on March 27, 2019, PPIX merged with and into PPIX Conversion Corp., PCA merged with and into PCA Conversion Corp., and PIPE merged with and into PIPE Conversion Corp. Accordingly, PPIX, PCA, and PIPE no longer exist. Immediately thereafter, PCA Conversion Corp. and PIPE Conversion Corp. merged with and into PPIX Conversion Corp., which then changed its name to Positive Physicians Insurance Company (“Positive Insurance Company”) and became our single insurance company subsidiary and successor to PPIX, PCA, and PIPE. ~~The~~PPHI ~~Company~~ had minimal assets and liabilities and had not engaged in any operations prior to March 27, 2019.

~~Overview~~Positive Insurance Company writes medical malpractice insurance for healthcare providers practicing in Pennsylvania, New Jersey, Ohio, Delaware, Maryland, South Carolina, and Michigan. Diversus Management, LLC (“Diversus Management”) manages and administers essentially all of ~~PPIX~~the operations of Positive Insurance Company under the terms of a management agreement. Diversus Management is a wholly owned subsidiary of Diversus, Inc. (“Diversus”). Pursuant to the terms of the agreement, effective March 27, 2019, Diversus Management provides such administrative services to Positive Insurance Company in exchange for fees based upon a percentage of Positive Insurance Company’s gross written premiums, less return premiums. Diversus Management may also earn quarterly performance management fees based on Positive Insurance Company’s combined ratio and net earned premiums. Positive Insurance Company remains responsible for all underwriting decisions and the payment of all claims and claims related expenses incurred under policies issued by Positive Insurance Company and for all sales commissions paid to producers.

~~PPIX~~Positive ~~was~~Insurance anCompany ~~unincorporated~~underwrites ~~exchange~~medical ~~organized~~professional onliability ~~April 20,~~coverage ~~2004~~for ~~and~~physicians, ~~was~~their ~~licensed~~corporations, bymedical ~~the~~groups, ~~Commonwealth~~clinics ofand ~~Pennsylvania~~allied ashealthcare ~~a reciprocal insurance exchange~~providers. ~~PPIX~~Medical ~~provided medical~~ professional liability insurance (“MPLI”) ~~consisting~~protects physicians and other health care providers against liabilities arising from the rendering of, or failure to render, professional medical services. We offer claims-made, ~~tail occurrence~~coverage, claims -made plus, and occurrence-based policies toas ~~its~~well ~~subscribers~~as ~~(policyholders). On~~tail ~~October 9,~~coverage ~~2018~~in Pennsylvania, ~~Positive~~New ~~Physicians~~Jersey, ~~Captive~~Ohio, ~~Insurance~~Delaware, ~~Company (“PPCIC”)~~Maryland, aSouth ~~sponsored~~Carolina, ~~captive~~and ~~insurance~~Michigan. Our ~~company,~~policies ~~was~~include ~~incorporated~~coverage infor the ~~State~~cost of ~~New~~defending ~~Jersey~~claims. Claims-made ~~and~~policies ~~became~~provide acoverage ~~wholly~~to ~~owned~~the ~~subsidiary~~policyholder for claims reported during the period of ~~PPIX~~coverage. ~~PPCIC~~We ~~was~~offer ~~licensed~~extended ~~under~~reporting ~~the~~endorsements, ~~New~~or ~~Jersey~~tails, ~~Captive~~to ~~Insurance~~cover ~~Act~~claims onreported ~~October 16,~~after ~~2018~~the policy expires. ~~PPCIC~~Occurrence-based ~~has~~policies ~~one~~provide ~~protected~~coverage ~~unincorporated~~to ~~cell,~~the ~~Keystone~~policyholders ~~Captive~~for ~~Group~~all ~~(“Keystone”)~~losses incurred during the policy coverage year regardless of when the claims are reported. ~~Keystone~~Although iswe ~~owned~~generate bya anmajority ~~insured~~ of ~~Positive~~our ~~Insurance~~premiums ~~Company~~from individual and small group practices, we also insure several major physician groups.

PPIX marketed its medical professional liability insurance policies directly to physicians and through independent producers to doctors and allied healthcare professionals who practice in Pennsylvania, Delaware, Maryland, New Jersey, and Ohio.

PPIX was managed by Specialty Insurance Services, LLC (“SIS”), a Pennsylvania limited liability company, pursuant to the terms of an Attorney-In-Fact Agreement between the exchange and SIS. SIS provided underwriting and administrative services to PPIX based on a percentage not to exceed 25% of gross written premiums, less return premiums. As the attorney-in-fact, SIS had the power to direct the activities of PPIX that most significantly impact PPIX’s economic performance. Diversus, Inc. (“Diversus”) acquired 100% of the ownership interests of SIS on January 1, 2017.

Overview of PCA

PCA was an unincorporated, reciprocal insurance association organized on April 16, 2003 and formed for the purpose of insuring its subscribers against loss due to the imposition of legal liability. PCA provided medical professional liability insurance consisting of claims-made, tail occurrence, and occurrence policies to its subscribers (policyholders).

PCA marketed its medical professional liability insurance policies through independent producers, primarily to doctors and allied healthcare providers who practice in Pennsylvania. In November 2015, PCA was granted a license to write insurance in Michigan and began writing policies in Michigan in the fourth quarter of 2015.

PCA was managed by Professional Third Party, LP (“PTP”), a Pennsylvania corporation, pursuant to the terms of an Attorney-in-Fact Agreement between the association and PTP. PTP provided salaries and benefit expenses of the employees, rent and other occupancy expenses, supplies, and data processing services to PCA, and paid certain expenses on behalf of PCA in exchange for 25% of gross written premium. As the attorney-in-fact, PTP had the power to direct the activities of PCA that most significantly impact PCA’s economic performance. Diversus acquired 100% of the ownership interests of PTP on June 4, 2014.

Overview of PIPE

PIPE was an unincorporated exchange organized on March 14, 2005 and was licensed by the Commonwealth of Pennsylvania as a reciprocal insurance exchange. PIPE provided medical professional liability insurance consisting of claims-made, tail occurrence, and occurrence policies to its subscribers (policyholders).

PIPE marketed its medical professional liability insurance policies through independent producers to doctors and allied healthcare professionals who practice primarily in Pennsylvania. PIPE also had a license and wrote business in South Carolina.

PIPE was managed by PIPE Management, a Pennsylvania corporation, pursuant to the terms of an Attorney-in-Fact Agreement between the exchange and PIPE Management. PIPE Management provided salaries and benefit expenses of the employees, rent and other occupancy expenses, supplies, and data processing services to PIPE, and paid certain expenses on behalf of PIPE in exchange for 25% of gross written premium. As the attorney-in-fact, PIPE Management had the power to direct the activities of PIPE that most significantly impact PIPE’s economic performance. Diversus acquired 100% of the ownership interests of PIPE Management on November 23, 2015.

SIS, PTP, and PIPE Management merged with and into Diversus Management, Inc. (“Diversus Management”) in connection with the conversions on March 27, 2019. Diversus Management is a wholly owned subsidiary of Diversus.

Marketplace Conditions and Trends

The MPLI industry is affected by recurring industry cycles known as “hard” and “soft” markets. A soft market is characterized by intense competition, resulting in lower pricing in order to compete for business. A hard market, generally considered a beneficial industry trend, is characterized by reduced competition that results in higher pricing. From approximately 2001 until approximately 2007, the Pennsylvania MPLI market experienced a hard market cycle. This resulted in the creation of several alternative MPLI providers, such as PPIX, PCA, and PIPE.

The MPLI market began to experience a soft market cycle around the second quarter of 2008, due primarily to the large rate increases taken over the previous six years. The soft market continued and was facilitated by the restructuring of the healthcare industry, partially as a result of the Affordable Care Act. This resulted in significant price competition, as the number of medical professionals practicing independent of hospitals or large professional groups began to decline. According to a study prepared by the National Association of Insurance Commissioners ~~(“NAIC”)~~, MPLI direct premiums written declined by 24.0% on a national basis from 2006 to 2018 and declined by 14.6% in Pennsylvania and 33.0% in New Jersey during this same time period. This resulted in lower direct premiums written and lower operating profits for many MPLI carriers.

The soft market cycle troughed in 2012, and since then, national loss payouts, on average, have steadily increased through 2019. As a result, underwriting criteria in the MPLI industry has started to become more stringent, with opportunities for improved pricing, and we believe the market cycle is currently transitioning to a hard market. At Positive Insurance Company, our renewal book of business in November 2019 has experienced price increases of 2.5% through reduced credits, a development which we expect to continue and extend through our policy renewals in 2020. We are also seeing rate increases take place by other carriers in many of the states in which we write business.20

InThe ~~addition~~soft tomarket ~~pricing~~cycle ~~increases,~~troughed in ~~what~~2012, weand ~~perceive~~since tothen, benational ~~the~~loss ~~beginnings~~payouts, ofon aaverage, ~~hard~~have ~~market~~steadily increased through 2019. As a result, weunderwriting ~~intend~~criteria toin ~~achieve~~the ~~further~~MPLI ~~premium~~industry ~~growth~~has started to become more stringent, with ~~our~~opportunities ~~expansion~~for ~~into~~improved ~~new~~pricing, ~~states~~and we believe the market cycle has transitioned to a hard market. At Positive Insurance Company, isbeginning ~~currently~~ in ~~the~~April ~~process~~2020 our renewal book of ~~obtaining~~business ~~licenses~~has begun to ~~write~~experience ~~business~~price inincreases ~~the~~of ~~states~~2.5% ofthrough ~~California,~~reduced ~~Connecticut~~credits, ~~Florida,~~a development which we expect to continue and ~~Texas~~extend through our policy renewals in 2020. We are also seeing rate increases take place by other carriers in many of the states in which we write business.

In addition to pricing increases, we intend to achieve further premium growth with our expansion into new states. Positive Insurance Company was admitted into Texas in November 2019 and is currently in the process of obtaining approval on premium rates before we can begin writing business there. We are also currently in the process of obtaining licenses to write business in the states of California and Florida.

Effects of COVID-19

Our operations and business have experienced disruptions due to the conditions surrounding the COVID-19 pandemic spreading throughout the United States. These disruptions include, but are not limited to, office closures and difficulties in maintaining operational continuance during remote operations required by illness, social quarantining, and work from home orders currently in force. Our management has devoted substantial time and attention to assessing the potential impact of COVID-19 and those events on our operations and financial position and developing operational and financial plans to address those matters.

As a result of the COVID-19 pandemic, we anticipate that premiums will decrease due to policy endorsements associated with doctors electing to work part time, take a leave of absence or retire. In addition, our insureds may elect to temporarily change their areas of practice and/or specialties. For example, a doctor may choose to drop from orthopedic surgery to office-only status due to the lack of elective surgeries. We have received notification for such requests from our policyholders which will go into effect on June 30, 2020 and necessary reimbursements or credits against future payments will be applied.

In terms of collections, prior to the pandemic, our policy was to cancel any insurance policies for which premiums had not been received within 60 days subsequent to policy effective date, with notice of intent to cancel sent to the insured after 30 days post-inception date, or post-payment due date. As a result of COVID-19, we have updated this policy and suspended cancellations of insurance contracts resulting from non-payment of premium and deferred payments until June 30, 2020 for invoices due after April 1, 2020. Through June 19, 2020, the amount of premium payment deferrals is about $950,000. Dependent upon the extent to which our policyholders’ own businesses have been impacted by the pandemic, our collection of premiums against current in-force policies could be significantly impacted.

With respect to claims, our policyholder base mainly consists of physicians, their corporations and medical groups. During the COVID-19 pandemic, on-site visits to doctors have declined and been replaced by an increase in telehealth/virtual office visits. Since the COVID-19 pandemic resulted in government-issued work from home orders, we have seen the number of new claims reported begin to decrease. In general, our expectation is that the frequency of new claims reported during this time period will decrease. As to actual claims relating to COVID-19 exposures, we anticipate that the number of claims will be minimal. Unless some unforeseen fact pattern is established, we expect that the difficulty of establishing the source of a COVID-19 exposure, as well as the heroic efforts of healthcare providers, will serve to make such claims unattractive to both patients and their counsel. We do not anticipate our loss and LAE ratios to be impacted. However, this view could change in the future depending on the duration of the pandemic and if the lower frequency of new claims reported becomes a trend.

Principal Revenue and Expense Items

Positive Insurance Company derives its revenue primarily from net premiums earned, net investment income, and net realized and unrealized gains (losses) from investments.

Net premiums earned

Gross premiums written is equal to direct and assumed premiums before the effect of ceded reinsurance. Net premiums written is the difference between gross premiums written and premiums ceded or paid to reinsurers (ceded premiums written).

Premiums earned are the earned portion of net premiums written. Gross premiums written include all premiums recorded by an insurance company during a specified policy period. Insurance premiums on MPLI policies are recognized in proportion to the underlying risk insured and are earned ratably over the duration of the policies. At the end of each accounting period, the portion of the premiums that is not yet earned is included in unearned premiums and recognized as revenue in subsequent periods over the remaining term of the policy. The policies written by Positive Insurance Company typically have a term of twelve months. Thus, for

2221

the premiums that is not yet earned is included in unearned premiums and recognized as revenue in subsequent periods over the remaining term of the policy. The policies written by Positive Insurance Company typically have a term of twelve months. Thus, for example, for a policy that is written on July 1, 2019, one-half of the premiums would be earned in 2019 and the other half would be earned in 2020.

Net investment income and net realized and unrealized gains (losses) from investments

We invest our surplus and the funds supporting our insurance liabilities (including unearned premiums and unpaid loss and loss adjustment expenses) in cash, cash equivalents, short-term investments, and equity and debt securities. Investment income includes interest and dividends earned. We recognize realized gains when invested assets are sold for an amount greater than their cost or amortized cost (in the case of fixed maturity securities) and recognize realized losses when investment securities are written down as a result of other-than-temporary-impairment or sold for an amount less than their cost or amortized cost, as applicable. Realized gains and losses on sales of fixed ~~income~~maturity and equity securities and other investments and unrealized holding gains and losses on equity securities and other investments are included in realized investment gains (losses), net. Our portfolio of investment securities is managed by our outside investment manager, who has discretion to buy and sell securities in accordance with the investment policy approved by Positive Insurance Company’s ~~board~~Board of ~~directors~~Directors.

Losses and loss adjustment expenses

Losses and loss adjustment expenses (“LAE”) represent the largest expense item and include: (1) claim payments made, (2) estimates for future claim payments and changes in those estimates for prior periods, and (3) costs associated with investigating, defending and adjusting claims, including legal fees.

Other underwriting expenses

Expenses incurred to underwrite risks include policy acquisition costs and underwriting and administrative expenses. Policy acquisition costs consist of commission expenses, premium taxes, and certain other underwriting expenses that vary with and are primarily related to the writing and acquisition of new and renewal business. These policy acquisition costs are deferred and amortized over the effective period of the related insurance policies. Underwriting and administrative expenses consist of salaries, rent, office supplies, depreciation, and all other operating expenses not otherwise classified separately, and payments to bureaus and assessments of statistical agencies for policy service and administration items such as rating manuals, rating plans and experience data.

Income taxes

We use the asset and liability method of accounting for income taxes. Deferred income taxes arise from the recognition of temporary differences between financial statement carrying amounts and the tax bases of our assets and liabilities. A valuation allowance is provided when it is more likely than not that some portion of the deferred tax asset will not be realized. The effect of a change in tax rates is recognized in the period of the enactment date.

Key Financial Measures

We evaluate our insurance operations by monitoring certain key measures of growth and profitability. InSome ~~addition~~of tothese ~~reviewing~~measurements ~~our~~are “non-GAAP” financial ~~performance~~measurements ~~based~~under onSecurities ~~results~~and ~~determined~~Exchange inCommission ~~accordance~~rules ~~with~~and ~~GAAP,~~regulations. We we utilize certain non-GAAP financial performance measures that are widely used in the property and casualty insurance industry and that we believe are valuable in managing our business and for comparison to our peers. These financial performance measures are the loss and ~~loss~~LAE ~~adjustment~~ratio, expense ratio, ~~expense~~combined ratio, underwriting income (loss), and ~~combined~~operating ~~ratio~~income (loss).

We measure growth by monitoring changes in gross premiums written and net premiums written, and measure underwriting profitability by examining ~~loss~~losses and ~~loss adjustment expense~~LAE, underwriting ~~expense~~expenses and combined ratios. We also measure profitability by examining underwriting income (loss) and operating income (loss).

Loss and ~~loss~~LAE ~~adjustment expense~~ ratio

The loss and ~~loss~~LAE ~~adjustment expense~~ ratio is the ratio (expressed as a percentage) of losses and loss adjustment expenses incurred to premiums earned. Positive Insurance Company measures the loss and LAE ratio on a policy year and calendar year loss basis to measure underwriting profitability. A policy year loss and LAE ratio measures losses and loss adjustment expenses for insured events occurring in a particular year, regardless of when they are reported, as a percentage of premiums earned during that year. A calendar year loss and LAE ratio measures losses and loss adjustment expenses for insured events occurring during a particular year and the change in loss reserves from prior policy years as a percentage of premiums earned during that year.

2322

Expense ratio

The expense ratio is the ratio (expressed as a percentage) of other underwriting expenses (attributable to insurance operations) to premiums earned, and measures our operational efficiency in producing, underwriting and administering the Company’s insurance business.

Combined ratio

The combined ratio is a measure of property and casualty underwriting performance. The combined ratio computed on a GAAP basis is equal to the sum of losses and loss adjustment expenses and other underwriting expenses, all divided by net premiums earned. If the combined ratio is below 100%, we are making an underwriting profit. If our combined ratio is at or above 100%, we are not profitable without investment income and may not be profitable if investment income is insufficient.

Underwriting income (loss)

Underwriting income (loss) measures the pre-tax profitability of insurance operations. It is derived by subtracting losses and loss adjustment expenses and other underwriting expenses from earned premiums.

Operating income (loss)

Operating income (loss) measures the profitability of business operations. We define it as GAAP net income (loss) excluding net realized investment gains and losses, net of tax. Net realized investment activity is excluded because net realized investment gains and losses are unpredictable and not necessarily indicative of current operating fundamentals or future performance of the business operations. Operating income is a non-GAAP measure which is important for an understanding of our overall results of operations. However, it does not replace net income (loss) as the GAAP measure of our consolidated results of operations, nor should it be viewed as a substitute for measures determined in accordance with GAAP.

RESULTS OF OPERATIONS

Our results of operations are influenced by factors affecting the MPLI industry, in general. The operating results of the United States MPLI industry are subject to significant variations due to competition, changes in regulation, rising medical expenses, judicial trends, fluctuations in interest rates, and other changes in the investment environment.

Our premium levels and underwriting results have been, and continue to be, influenced by market conditions. Pricing in the MPLI industry historically has been cyclical. During a soft market cycle, price competition is more significant than during a hard market cycle which makes it difficult to attract and retain properly priced MPLI business. As previously discussed, the markets in which we operate, and the national MPLI markets, ~~have~~were ~~been~~ in a prolonged period of a soft market cycle. However, we ~~have~~are ~~started~~seeing ~~to see~~ price increases with our policy renewals in ~~November~~2020 ~~2019~~ and we believe the market is ~~beginning to harden~~hardening. Therefore, it is generally likely that insurers will be able to increase their rates or profit margins, as market conditions continue to improve. A hard market typically has a positive effect on premium growth, which can include absolute increases in premiums written.

We had a ~~modest~~ net loss of $1,122,703 for the ~~third~~first quarter of ~~2019~~2020, compared to a net ~~loss~~income of $~~473~~91,~~400~~789 for the ~~third~~first quarter of ~~2018~~2019. ~~Operating~~The ~~income~~results ~~was~~for ~~$86,517~~both ~~for~~periods ~~the~~were ~~third~~significantly ~~quarter~~impacted ofby ~~2019,~~realized ~~compared~~investment to(losses) angains, ~~operating~~respectively, ~~loss~~mainly ofdue ~~$651,539~~to ~~for~~fluctuations in the ~~same~~unrealized ~~period~~position ~~last~~on ~~year~~our equity securities. ~~For~~Operating ~~the~~income ~~first~~was ~~nine months of 2019~~$429,190 wefor ~~had~~the afirst ~~net~~quarter ~~loss~~ of ~~$474~~2020,~~196,~~ compared to aan ~~net~~operating loss of $1581,~~619,045~~015 for the ~~first~~same ~~nine~~period ~~months~~last ~~in 2018~~year. WeThe ~~had~~increase ~~operating~~in ~~losses~~our ofoperating ~~$1,192,603~~results ~~and~~largely ~~$1,815,552~~reflects ~~for~~ the ~~first~~improvement ~~nine~~in ~~months~~our ofunderwriting ~~2019~~profitability, ~~and~~compared ~~2018,~~to ~~respectively~~prior year.

Total revenues were $3,486,586 in the ~~third~~first quarter of ~~2019 were $7~~2020,~~644,024,~~ compared to $6,~~182~~971,~~726~~114 for the same period inlast ~~2018~~year. ~~For~~The decline in revenues during the first ~~nine~~quarter ~~months~~ of ~~2019~~2020, ~~total~~compared ~~revenues~~to ~~were~~the ~~$20,882,997,~~first ~~compared~~quarter toin ~~$18~~2019,~~648,666~~ ~~for~~primarily ~~the~~reflects ~~first~~unrealized ~~nine~~losses ~~months~~on ofequity ~~2018. The~~securities ~~increases~~recognized in ~~revenues~~current ~~for~~year ~~both~~in ~~periods~~contrast into ~~2019,~~unrealized ~~compared~~gains torecorded in prior year,. To ~~primarily~~a ~~reflect~~lesser ~~new~~extent, ~~business~~net ~~which~~premiums ~~was~~ earned during the ~~third~~first quarter~~. The~~ ~~increase~~of in2020 ~~year-to-date revenues was~~ also ~~impacted~~decreased, bycompared ~~unrealized~~to ~~gains~~the onsame ~~equity~~period ~~securities recognized~~ in 2019.

2423

The major components of consolidated revenues and pre-tax income (loss) for the three ~~and nine~~ months ended ~~September~~March 3031, ~~2019~~2020 and ~~major~~2019 ~~components of combined revenues and pre-tax loss for the three and nine months ended September 30, 2018~~ are as follows ~~(unaudited)~~:

	Three Months Ended September 30,						Nine Months Ended September 30,
	Three Months Ended March 31,
	2019			2018			2019			2018
	2020			2019
Revenues:
Net premiums earned	$	64,~~989~~684,~~910~~710		$	5,~~293~~491,~~656~~207		$	~~17,809,111~~		$	~~16,485,313~~
Net investment income		~~770~~766,~~007~~297			~~663~~628,~~577~~256			~~2,164,510~~			~~1,914,610~~
Realized investment (losses) gains, net		(~~115~~1,~~893~~964,421	)		~~225~~851,~~493~~651			~~909,376~~			~~248,743~~
Total revenues		73,~~644~~486,~~024~~586			6,~~182~~971,~~726~~114			~~20,882,997~~			~~18,648,666~~
Expenses:
Losses and loss adjustment expenses		43,~~121~~185,~~056~~603			3,~~764~~321,~~202~~676			~~11,710,172~~			~~11,752,286~~
Other underwriting expenses		32,~~466~~338,~~905~~904			3,~~012~~500,~~002~~377			~~9,752,342~~			~~8,969,413~~
Underwriting income (loss)		56,063			(593,478	)		(579,517	)		(2,073,033	)
Interest expense		595			1,366
Interest expense		(912	)		(1,556	)		(2,691	)		(5,028	)
Total expenses		5,525,102			6,823,419
Income (loss) before income taxes		55(2,~~151~~038,516	)		~~(595~~147,~~034~~695	)		~~(582,208~~	)		~~(2,078,061~~	)
Income tax expense (benefit)		60(915,~~189~~813	)		~~(121~~55,~~634~~906	)		~~(108,012~~	)		~~(459,016~~	)
Net loss	$	(5,038	)	$	(473,400	)	$	(474,196	)	$	(1,619,045	)
Net income (loss)	$	(1,122,703	)	$	91,789
Underwriting loss (1)	$	(279,197	)	$	(1,130,446	)
Operating income (loss)	$	429,190		$	(581,015	)

(1)Underwriting loss excludes holding company expenses of $560,600 and $200,400 for the three months ended March 31, 2020 and 2019, respectively.

Premiums Written and Premiums Earned

The comparative changes in premiums written and premiums earned for the three ~~and nine~~ months ended ~~September~~March 3031, ~~2019~~2020 and ~~2018~~2019 are reflected in the ~~tables~~table below. ~~The increases in direct and net premiums for both periods are primarily due to new business written and earned during the third quarter of 2019.~~

	Three Months Ended September 30,
	Three Months Ended March 31,
	2019		2018		% Difference
	2020		2019		% Difference
Premiums written:
Direct	$	7,~~307~~718,~~405~~512	$	58,~~644~~197,~~259~~517		~~29.~~-5.8	%
Ceded		~~742~~246,~~219~~479		~~379~~1,~~552~~952,477		95-87.64	%
Premiums written, net of reinsurance	$	67,~~565~~472,~~186~~033	$	56,~~264~~245,~~707~~040		2419.76	%
Premiums earned:
Direct	$	75,~~969~~901,~~537~~448	$	6,~~222~~353,~~970~~380		28-7.1	%
Ceded		~~979~~1,~~627~~216,738		~~929~~862,~~314~~173		541.41	%
Premiums earned, net of reinsurance	$	64,~~989~~684,~~910~~710	$	5,~~293~~491,~~656~~207		32-14.07	%

	Nine Months Ended September 30,
	2019		2018		% Difference
Premiums written:
Direct	$	19,288,247	$	17,604,128		9.6	%
Ceded		3,342,950		2,546,976		31.3	%
Premiums written, net of reinsurance	$	15,945,297	$	15,057,152		5.9	%
Premiums earned:
Direct	$	20,398,452	$	18,958,037		7.6	%
Ceded		2,589,341		2,472,724		4.7	%
Premiums earned, net of reinsurance	$	17,809,111	$	16,485,313		8.0	%

The decline in direct premiums written during the first quarter of 2020, compared to the same period in 2019, is primarily due to the non-renewal of prior year policies which did not satisfy our underwriting criteria.

25Ceded premiums written significantly decreased during the first quarter of 2020, compared to the first quarter last year, as our ceded premiums are written based on direct premiums earned during the term of our reinsurance agreement. In 2020, our reinsurance agreement renewed on April 1st, whereas in 2019, our reinsurance contract renewed on March 27th. As a result, the amount of direct premiums subject to our calculation of ceded premiums written was much greater during the first quarter of 2019.

Net Investment Income

The following table sets forth our average cash and invested assets and investment income for the reported periods:

	Nine Months Ended September 30,
	Three Months Ended March 31,
	2019			2018
	2020			2019
Average cash and invested assets	$	~~112~~121,~~599~~949,~~817~~666		$	~~107~~112,~~803~~597,~~351~~331
Net investment income		2766,~~164,510~~297			1628,~~914,610~~256
Return on average cash and invested assets		1.92	%		1.78	%
Annualized return on average cash and invested assets		2.51	%		2.23	%

Net investment income for the ~~third~~first quarter of ~~2019~~2020 was $~~770~~766,~~007~~297, compared to $~~663~~628,~~577~~256 for the ~~third~~first quarter of ~~2018~~2019. The average monthly net investment income increased from $~~221~~209,000 during the ~~three~~first ~~months~~quarter ~~ended~~last ~~September~~year ~~30, 2018~~ to $~~257~~255,000 during the ~~three~~same ~~months~~period ~~ended~~this ~~September 30, 2019~~year.

~~Net~~The ~~investment~~increase ~~income for the first nine months~~ in ~~2019~~net ~~was~~investment ~~$2,164,510,~~income ~~compared~~primarily toreflects ~~$1,914,610 for~~ the ~~same~~increase ~~period~~ in ~~2018.~~our ~~The~~cash ~~average~~and ~~monthly~~invested ~~net~~asset ~~investment~~positions, ~~income~~due ~~increased~~to proceeds from ~~$213,000 during~~ the ~~nine~~initial ~~months~~public ~~ended~~offering ~~September~~stock ~~30,~~issuance ~~2018~~on toMarch ~~$240~~27,~~000~~ ~~during the nine months ended September 30,~~ 2019.

~~The~~Realized ~~increases~~Investment in(Losses) ~~net investment income for both periods primarily reflect increases in our cash and invested asset positions~~Gains, ~~resulting~~Net ~~from the initial public offering stock issuance.~~

~~Realized~~Net ~~Investment~~realized ~~Gains~~investment (~~Losses~~losses) gains for the three months ended March 31, ~~Net~~2020 and 2019 are as follows:

Realized net investment gains (losses) for the three and nine months ended September 30, 2019 and 2018 are as follows:

	Three Months Ended March 31,
	2020			2019
Total loss on sales of investments	$	(205,438	)	$	(34,946	)
Unrealized (loss) gain on equity securities and other investments		(1,758,983	)		886,597
Total net realized investment (losses) gains	$	(1,964,421	)	$	851,651

	Three Months Ended September 30,					Nine Months Ended September 30,
	2019			2018		2019			2018
Total (loss) gain on sales of investments	$	(736	)	$	40,227	$	(180,680	)	$	97,827
Unrealized (loss) gain on equity securities and other investments		(115,157	)		185,266		1,090,056			150,916
Total net realized investment (losses) gains	$	(115,893	)	$	225,493	$	909,376		$	248,743

The unrealized loss on equity securities for the first quarter of 2020 was temporary and primarily attributable to market volatility associated with the COVID-19 pandemic. During the second quarter of 2020, the fair value of our equity securities increased significantly, and we sold the majority of these holdings for a modest net realized gain. Our fixed maturity investments are available-for-sale because we may, from time to time, make sales of securities that are not impaired, consistent with our investment goals and policies.

Our fixed maturity investments and equity investments are available-for-sale because we may, from time to time, make sales of securities that are not impaired, consistent with our investment goals and policies.

Losses and Loss Adjustment Expenses

The components of the GAAP combined ratios were as follows:

	Three Months Ended September 30,						Nine Months Ended September 30,
	Three Months Ended March 31,
	2019			2018			2019			2018
	2020			2019
Loss and LAE ratio		5968.0	%		7160.15	%		~~65.8~~	%		~~71.3~~	%
Expense ratio (1)		4338.60	%		5660.91	%		~~48.8~~	%		~~54.4~~	%
Combined ratio		~~102~~106.60	%		~~128~~120.06	%		~~114.6~~	%		~~125.7~~	%

(1)Expense ratio excludes holding company expenses of $~~418~~560,~~000~~600 and $1200,~~054,000~~400 for the three ~~and nine~~ months ended ~~September~~March 3031, 2020 and 2019, respectively.

The ~~improved~~increase in the loss and LAE ratio for the ~~third~~first quarter of ~~2019 reflects lower loss estimates in the current accident year. During the nine months ended September 30~~2020, ~~2019,~~compared weto ~~experienced modest favorable~~ prior year ~~development~~, ~~compared~~reflects toa ~~unfavorable~~higher ~~prior year~~ loss ~~reserve~~and ~~development~~LAE ofestimate ~~$9,772,000~~ for the ~~same~~current ~~period~~policy ~~in 2018~~year.

The MPLI line of business is prone to variability in the loss reserving process due to the extended period of time during which claims can be made and the subsequent time required to settle those claims. Adjustments to our original estimates resulting from claims are not made until the period in which there is reasonable evidence that an adjustment to the reserve is appropriate.

2625

Other Underwriting Expenses

Other underwriting expenses, including changes in deferred acquisition costs, were $32,~~466~~338,~~905~~904 for the ~~third~~first quarter of ~~2019~~2020, compared to $3,~~012~~500,~~002~~377 for the ~~third~~first quarter of ~~2018. Other underwriting expenses, including changes in deferred acquisition costs, were $9,752,342 during the first nine months of~~ 2019~~, compared to $8,969,413 for the same period in 2018~~. ~~These amounts for 2019 include expenses incurred by the holding company which did not exist in prior year.~~ Positive Insurance Company pays a management fee to Diversus Management which is equal to a percentage of premiums written. This percentage was ~~25% in 2018 and was reduced to~~ 12%, ~~effective April 1, 2019. The reduction~~ in the ~~management~~first ~~fee~~quarter ~~partially~~of ~~offsets~~2020, ~~the~~compared ~~increases due~~ to ~~holding~~25% ~~company~~during ~~expenses~~the ~~for~~first ~~both~~quarter ~~periods~~last year. Positive Insurance Company also had $~~371~~391,~~000~~978 ~~and $487,000~~ in initial public offering and conversion costs that were expensed during the ~~nine~~three months ended ~~September~~March 3031, 2019 and ~~2018, respectively, and~~ are included in other underwriting expenses. These expense reductions in the current year were partially offset by the amortization of the prepaid management fee which was not incurred during the first quarter last year.

We are required to participate in the Pennsylvania Property and Casualty Insurance Guaranty ~~Fund~~Association (“PIGA”), which was formed to pay claims on policies issued by insolvent Pennsylvania domiciled property and casualty insurers. Each Pennsylvania domiciled property and casualty insurer pays PIGA an annual assessment based on its premiums written in Pennsylvania.

Income Tax Expense (Benefit)

The provision for income taxes for the three months ended ~~September~~March 3031, ~~2019~~2020 and ~~2018~~2019 resulted in an income tax ~~expense~~ (benefit) ofexpense ~~$60,189 and $(121,634), respectively. The provision for income taxes for the nine months ended September 30, 2019 and 2018 resulted in an income tax benefit~~ of $(~~108~~915,~~012~~813) and $~~(459~~55,~~016)~~906, respectively. The Company’s effective tax rate for ~~the~~both ~~nine~~periods ~~months ended September 30, 2019 and 2018~~ was 21%.

On March 27, 2020, President Trump signed the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) into law. The CARES Act includes certain income tax-related law changes that have a material effect on our deferred income taxes. The most significant effect on our deferred income taxes is due to changes in the federal net operating loss (“NOL”) carryback provisions which allow us to carryback NOLs originating in 2018 and 2019 to prior tax years with corporate income tax rates of 34% (as opposed to forward to future tax years with corporate income tax rates of 21%). As a result of this legislation, during the first quarter of 2020, we significantly reduced our NOL balance by $3,090,478, or $649,000 tax-effected, and recorded additional federal income tax refunds of $1,119,633, which resulted in an income tax benefit of $470,633.

Loss Reserves

The following ~~table~~tables ~~provides~~provide case and incurred-but-not-reported reserves of Positive Insurance Company’s losses and loss adjustment expenses as of ~~September~~March 3031, ~~2019~~2020 and December 31, ~~2018~~2019.

As of ~~September~~March 3031, ~~2019 (unaudited)~~2020

	Case Reserves		IBNR Reserves		Total Reserves
Medical professional liability	$	3032,~~772~~676,~~607~~232	$	2723,~~031~~743,~~278~~081	$	5756,~~803~~419,~~885~~313
Other		—		—		—
Total net reserves		32,676,232		23,743,081		56,419,313
Total net reserves		30,772,607		27,031,278		57,803,885
Reinsurance recoverables on unpaid claims		2,871,550		5,062,488		7,934,038
Reinsurance recoverables on unpaid claims		2,207,314		5,942,735		8,150,049
Gross reserves	$	35,547,782	$	28,805,569	$	64,353,351
Gross reserves	$	32,979,921	$	32,974,013	$	65,953,934

As of December 31, ~~2018 (combined unaudited)~~2019

	Case Reserves		IBNR Reserves		Total Reserves
Medical professional liability	$	30,~~741~~126,~~173~~567	$	2925,~~700~~966,~~908~~273	$	6056,~~442~~092,~~081~~840
Other		—		—		—
Total net reserves		30,126,567		25,966,273		56,092,840
Total net reserves		30,741,173		29,700,908		60,442,081
Reinsurance recoverables on unpaid claims		1,894,670		5,620,465		7,515,135
Reinsurance recoverables on unpaid claims		1,613,765		6,336,487		7,950,252
Gross reserves	$	32,021,237	$	31,586,738	$	63,607,975
Gross reserves	$	32,354,938	$	36,037,395	$	68,392,333

The estimation of Positive Insurance Company’s reserves is based on several actuarial methods, each of which incorporates many quantitative assumptions. The judgment of the independent actuary plays an important role in selecting among various loss development factors and selecting the appropriate method, or combination of methods, to use for a given policy year.

2726

LIQUIDITY AND CAPITAL RESOURCES

Liquidity is a measure of an entity’s ability to secure sufficient cash to meet its contractual obligations and operating needs. Our insurance operations generate cash by writing policies and collecting premiums. The cash generated is used to pay losses and LAE as well as other underwriting expenses. Any excess cash is invested and earns investment income.

We ~~maintained~~maintain investment and reinsurance programs that are intended to provide sufficient funds to meet our obligations without forced sales of investments. As such, our investment portfolio contains a high degree of liquidity, with relatively short-term and highly liquid assets, to ensure the availability of funds and to meet the demands of claim settlements and operating expenses. We also have an Investment Committee which meets regularly to discuss cash flow projections and our short-term cash needs as well as asset allocation within our investment portfolio.

Furthermore, liquidity requirements are met primarily through operating cash flows and by maintaining a portfolio with maturities that reflect our estimates of future cash flow requirements. Our investment strategy includes setting guidelines for asset quality standards, allocating assets among investment types and issuers, and other relevant criteria for our portfolio. In addition, invested asset cash flows, which include both current interest income received and investment maturities, are structured to consider projected liability cash flows of loss reserve payouts that are based on actuarial models. Property and casualty claim demands are somewhat unpredictable in nature and require liquidity from the underlying invested assets. Our invested assets are structured to emphasize current investment income while maintaining appropriate portfolio quality and diversity.

Cash flows for the ~~nine~~three months ended ~~September~~March 3031, ~~2019~~2020 and ~~2018~~2019 were as follows:

	Nine Months Ended September 30,
	Three Months Ended March 31,
	2019			2018
	2020			2019
	(Unaudited)			(Unaudited Combined)
Cash flows provided by (used in) operating activities	$	147,745		$	(12,447,833	)
Cash flows used in operating activities	$	(14,236,706	)	$	(4,496,316	)
Cash flows provided by investing activities		799,053			4,812,629
Cash flows (used in) provided by investing activities		(4,507,732	)		1,014,560
Cash flows (used in) provided by financing activities		(16,004	)		33,601,849
Cash flows provided by (used in) financing activities		33,527,777			(44,247	)
Net increase in cash and cash equivalents	$	930,794		$	25,966,645
Net increase (decrease) in cash and cash equivalents	$	14,783,339		$	(3,526,003	)

Cash flows ~~used~~from in operating activities ~~increased~~improved during the first ~~nine~~three months of ~~2019~~2020, compared to prior year, primarily attributable to the ~~current year~~ payment of the $10,000,000 prepaid management fee to Diversus in 2019. Cash flows from investing activities decreased in the first ~~nine~~three months of ~~2019~~2020, compared to prior year, mainly due to ~~lower~~additional ~~proceeds~~purchases ~~from~~of ~~sales~~fixed ~~and~~maturity ~~maturities~~securities onin ~~our~~the ~~fixed~~current ~~income portfolio~~year. The ~~increase~~decrease in cash flows from financing activities in 2020 reflects proceeds of $33,617,080 received from the initial public offering stock issuance ~~of $33,574,401~~ in March 2019.

At the holding company level, our primary sources of liquidity are dividends and tax payments received from Positive Insurance Company and capital raising activities. We utilize cash to pay debt obligations, taxes to the federal government, and corporate expenses. At ~~September~~March 3031, ~~2019~~2020, we had $1716,~~381~~786,~~892~~967 of cash and short-term investments at our holding company which we believe, combined with our other capital sources, will continue to provide us with sufficient funds to meet our foreseeable ongoing expenses and other obligations.

Our insurance subsidiary, Positive Insurance Company, is restricted by the insurance laws and regulations of the Commonwealth of Pennsylvania as to the amount of dividends or other distributions it may pay to the holding company. In considering future dividend policy, Positive Insurance Company will consider, among other things, applicable regulatory constraints. AsAt ofMarch ~~September 30~~31, ~~2019~~2020, Positive Insurance Company had statutory surplus of $3837,~~463~~669,~~166~~171.

An order by the Pennsylvania Insurance Department approving the conversions of PPIX, PCA, and PIPE prohibits the declaration or payment of any dividend, return of capital, or other distribution by ~~the~~PPHI ~~Company~~ to Insurance Capital Group, LLC and Enstar Holdings (US) LLC, the two principal stockholders of ~~the Company~~PPHI, or any other shareholder without the prior approval of the Pennsylvania Insurance Department, for a period of three years following the effective date of the conversions. Additionally, by the order of the Pennsylvania Insurance Department, Positive Insurance Company cannot pay a dividend to ~~the~~PPHI ~~Company~~ for a period of three years following the effective date of the conversions without the approval of the Pennsylvania Insurance Department.

28Prior to its payment of any dividend, Positive Insurance Company will be required to provide notice of the dividend to the Pennsylvania Insurance Department. This notice must be provided to the Pennsylvania Insurance Department 30 days prior to the payment of an extraordinary dividend and 10 days prior to the payment of an ordinary dividend. The Pennsylvania Insurance

~~Upon~~Department ~~completion~~has of the ~~offering~~power ~~on March 27, 2019, the Company is a public company and is subject~~ to ~~the~~limit ~~proxy~~or ~~solicitation,~~prohibit ~~periodic~~dividends ~~reporting,~~if ~~insider~~Positive ~~trading~~Insurance ~~and other requirements of the Exchange Act and to most of the provisions of the Sarbanes-Oxley Act of 2002. As a result, the~~ Company ~~anticipates~~is ~~incurring significant increases~~ in ~~expenses~~violation ~~related~~of toany ~~accounting~~law ~~and~~or ~~legal services that will be necessary to comply with such requirements~~regulation. WeThese ~~estimate~~restrictions ~~that~~or ~~the~~any ~~cost~~subsequently ofimposed ~~initial~~restrictions ~~compliance~~may ~~with~~affect ~~the~~our ~~requirements~~future of the Sarbanes-Oxley Act will be approximately $350,000 and that compliance with the ongoing requirements of the Exchange Act and the Sarbanes-Oxley Act will result in an increase of approximately $200,000 in annual operating expensesliquidity.

Off-Balance Sheet Arrangements

The Company had no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, results of operations, liquidity, capital expenditures, or capital reserves.

INVESTMENTS

Our investment portfolio is invested primarily in publicly traded, investment grade, fixed ~~income~~maturity securities with an average credit quality of A as rated by nationally recognized credit rating agencies. The portfolio is externally managed by independent, professional investment managers and is broadly diversified across sectors and issuers. Exposures are aggregated, monitored, and actively managed by our Investment Committee. We also have an investment policy statement which requires managers to maintain highly diversified exposures to individual issuers and closely monitor compliance with portfolio guidelines.

We have structured our investment portfolio to provide an appropriate matching of maturities with anticipated claims payments. The fair values of these investments are subject to fluctuation in interest rates. If we decide or are required in the future to sell securities in a rising interest rate environment, then we would expect to incur losses from such sales. As of March 31, 2020, the average duration of our fixed ~~income~~maturity ~~securities~~security investments that support the insurance reserves was 3approximately was 2.09 years, atwhile ~~September~~the 30duration of our insurance reserves was slightly lower, ~~2019~~reflecting our decision to maintain longer asset duration in order to enhance overall yield, ~~and~~while wemaintaining a high overall credit quality. We estimate that a 100 basis points (bps) increase in interest rates would reduce the valuation of our fixed ~~income~~maturity portfolio by $3,~~327~~204,~~222~~583 at ~~September~~March 3031, ~~2019~~2020.

~~Our~~The ~~investment~~following ~~portfolio~~table ~~also~~shows ~~includes equity securities and other investments, which consist of limited partnership equity hedge funds. We intend to sell our other investments in~~ the ~~near term and remove the risks associated with them from our portfolio. At September 30, 2019, the~~ fair value and amortized cost/cost ~~basis~~ of ~~these~~our ~~investments~~available-for-sale ~~were~~fixed ~~$3,320,010~~maturity and ~~$2,800,000,~~equity ~~respectively.~~securities:

The following table shows the fair value and amortized cost/cost of our available-for-sale bond and equity securities:

	March 31, 2020				December 31, 2019
	Fair Value		Amortized Cost/Cost		Fair Value		Amortized Cost/Cost
U.S. government	$	9,521,739	$	9,323,710	$	10,751,562	$	10,689,829
States, territories, and possessions		1,133,073		1,092,785		1,143,023		1,096,638
Subdivisions of states, territories, and possessions		12,675,693		12,375,653		12,822,865		12,440,863
Industrial and miscellaneous		66,471,482		67,258,447		71,030,592		69,445,114
Total fixed maturity securities		89,801,987		90,050,595		95,748,042		93,672,444
Equity securities		5,868,709		6,473,187		7,756,966		7,267,094
	$	95,670,696	$	96,523,782	$	103,505,008	$	100,939,538

	September 30, 2019				December 31, 2018
	Fair Value		Amortized Cost/Cost		Fair Value		Amortized Cost/Cost
U.S. government	$	12,866,267	$	12,798,909	$	12,737,756	$	12,859,101
States, territories, and possessions		1,149,782		1,100,524		1,125,479		1,111,879
Subdivisions of states, territories, and possessions		12,878,295		12,531,299		13,292,064		13,230,690
Industrial and miscellaneous		66,344,358		64,875,153		58,051,370		59,561,984
Total bonds		93,238,702		91,305,885		85,206,669		86,763,654
Equity securities		7,351,646		6,579,604		7,267,094		7,568,810
	$	100,590,348	$	97,885,489	$	92,473,763	$	94,332,464

The fair value of our investment portfolio declined during the first quarter of 2020, primarily attributable to market volatility associated with the COVID-19 pandemic and fluctuations in interest rates. The total net unrealized loss on these securities at March 31, 2020 was $853,086, or nearly 1% of the amortized cost or cost basis, compared to an overall net unrealized gain of $3,230,102 at December 31, 2019. During the second quarter of 2020, the fair value of our equity securities increased significantly, and we sold the majority of these holdings for a modest net realized gain in order to de-risk our consolidated balance sheet.

~~The fair value of these securities increased $8,116,585 during the nine months ended September 30, 2019, primarily due~~ Year-to-date ~~the~~movements ~~investing~~in ~~of net proceeds from~~ the ~~initial public offering stock issuance and~~ unrealized ~~appreciation driven by declining interest rates. The net unrealized~~ gain on(loss) ~~these~~position ~~securities at September 30, 2019 was $2,704,859, or nearly 3%~~ of ~~the~~our ~~amortized~~fixed ~~cost~~maturity ~~or cost basis. The net unrealized gain included gross unrealized gains of $3,153,477~~ and ~~gross~~equity ~~unrealized~~securities ~~losses~~are ofas ~~$448,618.~~follows:

	March 31, 2020			December 31, 2019			YTD Change
Fixed maturity securities:
Unrealized gains	$	1,543,691		$	2,127,857		$	(584,166	)
Unrealized losses		(1,792,299	)		(52,259	)		(1,740,040	)
Net fixed maturity securities unrealized (losses) gains		(248,608	)		2,075,598			(2,324,206	)
Equity securities:
Unrealized gains		462,161			1,493,581			(1,031,420	)
Unrealized losses		(1,066,639	)		(339,077	)		(727,562	)
Net equity securities unrealized (losses) gains		(604,478	)		1,154,504			(1,758,982	)
Net unrealized (loss) gain	$	(853,086	)	$	3,230,102		$	(4,083,188	)

For securities that were in an unrealized loss position at September 30, 2019, the length of time that such securities were in an unrealized loss position, as measured by their month-end fair value, was as follows:28

	Less than 12 months				12 months or longer				Total
Description of securities	Fair Value		Unrealized Losses		Fair Value		Unrealized Losses		Fair Value		Unrealized Losses
September 30, 2019:
U.S. government	$	3,424,282	$	9,856	$	5,336,033	$	40,927	$	8,760,315	$	50,783
Subdivisions of states, territories, and possessions		—		—		139,500		11,231		139,500		11,231
Industrial and miscellaneous		4,338,594		9,577		3,493,028		11,590		7,831,622		21,167
Total fixed maturities		7,762,876		19,433		8,968,561		63,748		16,731,437		83,181
Equity securities		834,110		48,272		698,627		317,165		1,532,737		365,437
Total temporarily impaired securities	$	8,596,986	$	67,705	$	9,667,188	$	380,913	$	18,264,174	$	448,618

For our fixed maturity securities that were temporarily impaired at March 31, 2020 and December 31, 2019, the length of time that such securities were in an unrealized loss position, as measured by their month-end fair value, are as follows:

At September 30, 2019, we had gross unrealized losses on fixed maturity securities of $83,181, compared to gross unrealized losses on fixed maturity securities of $1,778,831 at December 31, 2018. Most of these unrealized losses were attributable to fluctuations in interest rates. We have not observed any evidence which would lead us to believe that the entire amortized cost basis will not be recovered.

	Less than 12 months				12 months or longer				Total
Description of securities	Fair Value		Unrealized Losses		Fair Value		Unrealized Losses		Fair Value		Unrealized Losses
March 31, 2020:
U.S. government	$	—	$	—	$	492,985	$	17,108	$	492,985	$	17,108
States, territories, and possessions		—		—		—		—		—		—
Subdivisions of states, territories, and possessions		152,274		6,312		68,354		6,985		220,628		13,297
Industrial and miscellaneous		28,285,031		1,761,894		—		—		28,285,031		1,761,894
Total fixed maturity securities	$	28,437,305	$	1,768,206	$	561,339	$	24,093	$	28,998,644	$	1,792,299

	Less than 12 months				12 months or longer				Total
Description of securities	Fair Value		Unrealized Losses		Fair Value		Unrealized Losses		Fair Value		Unrealized Losses
December 31, 2019:
U.S. government	$	2,628,516	$	8,227	$	4,061,077	$	30,263	$	6,689,593	$	38,490
States, territories, and possessions		—		—		—		—		—		—
Subdivisions of states, territories, and possessions		—		—		93,000		7,470		93,000		7,470
Industrial and miscellaneous		4,773,607		5,934		350,922		365		5,124,529		6,299
Total fixed maturity securities	$	7,402,123	$	14,161	$	4,504,999	$	38,098	$	11,907,122	$	52,259

At March 31, 2020, we had gross unrealized losses on fixed maturity securities of $1,792,299, compared to gross unrealized losses on fixed maturity securities of $52,259 at December 31, 2019. The increase in gross unrealized losses during the first quarter was attributable to increases in interest rates, mainly associated with our holdings in corporate bonds. We have not observed any evidence which would lead us to believe that the entire amortized cost basis will not be recovered, and many of these positions have since improved in the second quarter.

OTHER MATTERS

Comparison of SAP and GAAP Results

Results presented in accordance with GAAP vary in certain respects from results presented in accordance with statutory accounting practices prescribed or permitted by the Pennsylvania Insurance Department (collectively “SAP”). Prescribed SAP includes state laws, regulations and general administrative rules, as well as a variety of National Association of Insurance Commissioners publications. Permitted SAP encompasses all accounting practices that are not prescribed. Our domestic insurance subsidiary uses SAP to prepare various financial reports for use by insurance regulators.

Recent Accounting Guidance

Refer to Note 4 to the Unaudited Consolidated Financial Statements for information regarding recent accounting guidance.

Critical Accounting Policies

As of ~~September~~March 3031, ~~2019~~2020, there were no material changes to our critical accounting estimates. For a full discussion of our critical accounting estimates, refer to Item 7 in our ~~2018~~2019 Form 10-K.

3029

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This report ~~contains~~may contain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995 with respect to the Company’s business, financial condition and results of operations and the plans and objectives of its management. Forward-looking statements can generally be identified by use of forward-looking terminology such as “may,” “will,” “plan,” “expect,” “intend,” “anticipate,” and “believe.” These forward-looking statements may include estimates, assumptions or projections and are based on currently available financial, industry, competitive and economic data and our current operating plans. All forward-looking statements are subject to risks and uncertainties, including risks regarding the effects and duration of the COVID-19 pandemic, that could cause actual results to differ materially from those expressed or implied by the forward-looking statements.

The ~~factors~~effect ~~that~~of the COVID-19 pandemic on our operations could ~~cause~~have ~~actual~~a material adverse effect on our business, financial condition, results toof ~~differ~~operations, ~~materially~~or ~~from~~cash ~~those~~flows. The World Health Organization has declared the outbreak of COVID-19, which began in December 2019, a pandemic and the ~~forward~~U.S. federal government has declared it a national emergency. Our business and operations could be materially and adversely affected by the effects of COVID-~~looking~~19. ~~statements~~The global spread of COVID-19 has already created significant volatility, ~~include~~uncertainty and economic disruption in the markets in which we operate. Governments, ~~but~~public institutions, and other organizations in countries and localities where cases of COVID-19 have been detected are ~~not~~taking ~~limited~~certain emergency measures to: mitigate its spread, including implementing travel restrictions and closing factories, schools, public buildings, and businesses. While the full impact of this outbreak is not yet known, we are closely monitoring the spread of COVID-19 and continually assessing its potential effects on our business.

As a result of current restrictions put in place to address COVID-19 and the related economic downturn, the Company has experienced business disruptions including, but not limited to, office closures and difficulties in maintaining operational continuance during remote operations required by illness, social quarantining, and work from home orders currently in force. The extent to which our results continue to be affected by COVID-19 will largely depend on future developments which cannot be accurately predicted, including the duration and scope of the pandemic, governmental and business responses to the pandemic and the impact on the global economy. While these factors are uncertain, the COVID-19 pandemic or the perception of its effects could continue to have a material adverse effect on our business, financial condition, results of operations, or cash flows.

Other factors that could cause actual results to differ materially from those in the forward-looking statements, include, but are not limited to:

•

the potential impact of fraud, operational errors, system malfunctions, or cybersecurity incidents;

•

financial market conditions, including, but not limited to, changes in interest rates and the stock markets causing a reduction of investment income or investment gains and reduction in the value of our investment portfolio;

•

future economic conditions in the market in which we compete that are less favorable than expected;

•

the effect of legislative, judicial, economic, demographic, and regulatory events in the jurisdictions where we do business;

•

our ability to successfully implement steps to optimize the business portfolio, ensure capital efficiency, and enhance investment returns;

•

the risks associated with the management of capital on behalf of investors;

•

our ability to enter new markets successfully and capitalize on growth opportunities either through acquisitions or the expansion of our producer network;

•

the success with which our brokers sell our products and our ability to collect payments from our insureds;

•

heightened competition, including specifically the intensification of price competition, the entry of new competitors and the development of new products by new or existing competitors, resulting in a reduction in the demand for our products;

•

our concentration in medical professional liability insurance, which makes us particularly susceptible to adverse changes in that industry segment;

•

changes in general economic conditions, including inflation, unemployment, interest rates and other factors;

•

estimates and adequacy of loss reserves and trends in loss and loss adjustment expenses;

•

changes in the coverage terms required by state laws, including higher limits;

•

our inability to obtain regulatory approval of, or to implement, premium rate increases;

•

inadequacy of premiums we charge to compensate us for our losses incurred;

•

the effectiveness of our risk management loss limitation methods;

•

our ability to obtain reinsurance coverage at reasonable prices or on terms that adequately protect us and to collect amounts that we believe we are entitled to under such reinsurance;

•

our ability to attract and retain qualified management personnel;

• dependence upon our relationship with Diversus Management, LLC and the management fee under our agreement with them;

• the potential impact on our reported net income (loss) that could result from the adoption of future accounting standards issued by the Financial Accounting Standards Board or other standard-setting bodies;

•

unanticipated changes in industry trends and ratings assigned by nationally recognized rating organizations;

•

statutory requirements that limit our ability to receive dividends from our insurance subsidiary;

•

the impact of future results on the recoverability of our deferred tax asset;

•

adverse litigation or arbitration results; and

•

adverse changes in applicable laws, regulations or rules governing insurance holding companies and insurance companies, including tax or accounting matters, limitations on premium levels, increases in minimum capital and reserves, other financial viability requirements, and changes that affect the cost of, or demand for, our products.

You should not place undue reliance on any forward-looking statements that we make. All forward-looking statements made in this Form 10-Q reflect our views on the date of this report. Forward-looking statements are not generally required to be publicly revised as circumstances change and we do not intend to update the forward-looking statements in this Form 10-Q to reflect circumstances after the date of this report or to reflect the occurrence of unanticipated events.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Market Risk

Market risk is the risk that a company will incur losses due to adverse changes in the fair value of financial instruments. We have exposure to three principal types of market risk through our investment activities: interest rate risk, credit risk and equity risk. Our primary market risk exposure is changes in interest rates. We have not entered, and do not plan to enter, into any derivative financial instruments for hedging, trading or speculative purposes.

Interest Rate Risk

Interest rate risk is the risk that a company will incur economic losses due to adverse changes in interest rates. Our exposure to interest rate changes primarily results from our significant holdings of fixed rate investments. Fluctuations in interest rates have a direct impact on the fair value of these securities.

~~The average duration of the fixed maturity securities in our investment portfolio at September 30, 2019 was 3.0 years.~~ Our fixed maturity investments include U.S. government bonds, securities issued by government agencies, obligations of state and local governments and governmental authorities, and corporate bonds, most of which are exposed to changes in prevailing interest rates and which may experience moderate fluctuations in fair value resulting from changes in interest rates. We hold these investments as available for sale. This allows us to manage our exposure to risks associated with interest rate fluctuations through active review of our investment portfolio by management, our investment adviser and our board of directors.

Fluctuations in near-term interest rates could impact our results of operations and operating cash flows. Certain of these securities may have call features. In a declining interest rate environment these securities may be called by their issuer and replaced with securities bearing lower interest rates. If we are required to sell these securities in a rising interest rate environment, then we may recognize losses.

As a general matter, we attempt to match the durations of our assets with the durations of our liabilities. Our investment objectives include maintaining adequate liquidity to meet our operational needs and optimizing our after-tax investment income and our after-tax total return, all of which are subject to our tolerance for risk.

The table below shows the interest rate sensitivity on our fixed maturity investments measured in terms of fair value (which is equal to the carrying value for all of our investment securities that are subject to interest rate changes) at ~~September~~March 3031, ~~2019~~2020:

Hypothetical Change in	Estimated Change			Fair
Interest Rates	in Fair Value			Value
200 basis point increase	$	(6,~~660~~414,~~040~~556	)	$	8683,~~578~~387,~~662~~431
100 basis point increase		(3,~~327~~204,~~222~~583	)		8986,~~911~~597,~~480~~404
No change					9389,~~238~~801,~~702~~987
100 basis point decrease		3,~~309~~187,~~974~~971			9692,~~548~~989,~~676~~958
200 basis point decrease		6,~~642~~397,~~325~~494			9996,~~881~~199,~~027~~481

Credit Risk

Credit risk is the potential economic loss principally arising from adverse changes in the financial condition of a specific debt issuer. We address this risk by investing primarily in fixed maturity securities that are rated at least “A” by Moody’s or an equivalent rating quality. We also independently, and through our outside investment manager, monitor the financial condition of all the issuers of fixed maturity securities in our portfolio. To limit our exposure to risk, we employ diversification rules that limit the credit exposure to any single issuer or asset class.

Equity Risk

Equity price risk is the risk that we will incur economic losses on our equity securities due to adverse changes in equity prices.

Impact of Inflation

Increases in the cost of medical procedures and related services can affect the losses that we may incur in connection with resolving claims under policies that we issue. These cost increases reduce profit margins to the extent that rate increases are not implemented on an adequate and timely basis. We, like all insurance companies, establish insurance premium levels before the amount of losses and loss adjustment expenses, or the extent to which inflation may impact these expenses, are known. Therefore, we attempt to anticipate the potential impact of inflation when establishing rates. Because inflation has remained relatively low in recent years, our financial results have not been significantly affected by it.

Item 4. Controls and Procedures.

A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected.

Disclosure Controls and Procedures

The Company maintains disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), that are designed to ensure that required information is recorded, processed, summarized and reported within the required timeframe as specified in the SEC’s rules and forms of the SEC. Our disclosure controls and procedures are also designed to ensure that information required to be disclosed is accumulated and communicated to the Company’s management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.

In connection with the preparation of this Quarterly Report on Form 10-Q, we carried out an evaluation under the supervision of and with the participation of management, including the Chief Executive Officer and the Chief Financial Officer, as of ~~September~~March 3031, ~~2019~~2020, of the effectiveness of the design and operation of our disclosure controls and procedures. Based upon this evaluation, the Chief Executive Officer and the Chief Financial Officer concluded that as of ~~September~~March 3031, ~~2019~~2020, our disclosure controls and procedures were effective and timely at the reasonable assurance level.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) of the Exchange Act) identified during the ~~third~~first quarter of ~~2019~~2020 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

PART II—OTHER INFORMATION

Item 1. Legal Proceedings.

Positive ~~Insurance~~Physicians Holdings, Inc. and its wholly owned subsidiary (collectively referred to as the “Company”) isare periodically subject to litigation in the normal course of its business. Based upon information presently available to us, we do not consider any litigation to be material. However, given the uncertainties attendant to litigation, we cannot assure you that our results of operations and financial condition will not be materially adversely affected by any litigation.

Item 1A. Risk Factors.

Not required.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None

Item 3. Defaults Upon Senior Securities.

None

Item 4. Mine Safety Disclosures.

Not applicable

Item 5. Other Information.

~~None~~The Company is filing this Form 10-Q for first quarter after the May 15, 2020 deadline otherwise applicable to such filing (the “Original Deadline”) in reliance on the 45-day extension provided by an order issued by the U.S. Securities and Exchange Commission (the “SEC”) under Section 36 of the Securities Exchange Act of 1934, as amended, dated March 4, 2020 (Release No. 34-88318), as modified and superseded by a new SEC order issued on March 25, 2020 (Release No. 34-88465) (collectively, the “Order”). The reasons why the Company could not file the Form 10-Q for first quarter on a timely basis before the Original Deadline are described below.

On May 15, 2020, the Company filed a Current Report on Form 8-K with the SEC (the “Form 8-K”) to indicate its intention to rely on the Order for a filing extension in connection with the Company’s filing of the Form 10-Q for first quarter. Consistent with the Company’s statements made in the Form 8-K, the Company was unable to file the Form 10-Q prior to the Original Deadline due to circumstances related to the coronavirus disease 2019 (COVID-19). The Company’s operations and business have experienced disruptions due to the conditions surrounding the COVID-19 pandemic spreading throughout the United States. These disruptions include, but are not limited to, office closures and difficulties in maintaining operational continuance during remote operations required by illness, social quarantining, and work from home orders. The Company’s management has devoted substantial time and attention to assessing the potential impact of COVID-19 and those events on the Company’s operations and financial position and developing operational and financial plans to address those matters, which has diverted management resources from completing all of the tasks necessary to file the Form 10-Q for first quarter by the Original Deadline. Accordingly, the Company relied on the Order because it was unable to timely file the Form 10-Q by the Original Deadline without undue hardship and expense to the Company due to COVID-19.

Item 6. Exhibits.

Furnish the exhibits required by Item 601 of Regulation S-K (§ 229.601 of this chapter).

Exhibit Number		Description
3.1		Amended and Restated Articles of Incorporation of Positive Physicians Holdings, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant’s Registration Statement on Form S-1 (333-229322)).
31.1*		Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
3.2		Bylaws of Positive Physicians Holdings, Inc. (incorporated by reference to Exhibit 3.2 to the Registrant’s Registration Statement on Form S-1 (333-229322)).
31.2*		Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
10.1		Management Agreement between Positive Physicians Insurance Company, Positive Physicians Holdings, Inc., Diversus Management, Inc., and Diversus, Inc. dated March 27, 2019 (incorporated by reference to Exhibit 10.1 to the Registrant’s Annual Report on Form 10-K on April 24, 2019).
32.1*		Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
10.2		Standby Stock Purchase Agreement dated as of June 8, 2018, among Insurance Capital Group, LLC, Positive Physicians Insurance Exchange, Professional Casualty Association, Physician’s Insurance Program Exchange, and Positive Physicians Holdings, Inc. (incorporated by reference to Exhibit 10.2 to the Registrant’s Registration Statement on Form S-1 (333-229322)).
32.2*		Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
10.3		Amendment to Standby Stock Purchase Agreement dated as of September 21, 2018, among Insurance Capital Group, LLC, Positive Physicians Insurance Exchange, Professional Casualty Association, Physician’s Insurance Program Exchange, and Positive Physicians Holdings, Inc. (incorporated by reference to Exhibit 10.3 to the Registrant’s Registration Statement on Form S-1 (333-229322)).
101.INS		XBRL Instance Document
10.4		Amendment No. 2 to the Standby Stock Purchase Agreement dated as of December 6, 2018, among Insurance Capital Group, LLC, Positive Physicians Insurance Exchange, Professional Casualty Association, Physicians’ Insurance Program Exchange, and Positive Physicians Holdings, Inc. (incorporated by reference to Exhibit 10.4 to the Registrant’s Registration Statement on Form S-1 (333-229322)).
101.SCH		XBRL Taxonomy Extension Schema Document
10.5		Amended and restated Supplemental Agreement dated September 21, 2018, among Diversus, Inc., Insurance Capital Group, LLC, Positive Physicians Insurance Exchange, Professional Casualty Association, Physician’s Insurance Program Exchange, and Positive Physicians Holdings, Inc. (incorporated by reference to Exhibit 10.5 to the Registrant’s Registration Statement on Form S-1 (333-229322)).
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document
10.6		Option Agreement among Diversus, Inc., Insurance Capital Group, LLC, and Positive Physicians Holdings, Inc. dated March 27, 2019 (incorporated by reference to Exhibit 10.6 to the Registrant’s Annual Report on Form 10-K filed on April 24, 2019).
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document
10.7		Management Services Agreement between Positive Physicians Holdings, Inc. and Diversus Management Inc. dated March 27, 2019 (incorporated by reference to Exhibit 10.7 to the Registrant’s Annual Report on Form 10-K filed on April 24, 2019).
101.LAB		XBRL Taxonomy Extension Label Linkbase Document
10.8		Medical Malpractice Working Excess Reinsurance Contract effective January 1, 2018 between Hannover Ruck Se and Positive Physicians Insurance Exchange (incorporated by reference to Exhibit 10.8 to the Registrant’s Registration Statement on Form S-1 (333-229322)).
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document
10.9		Governance Agreement dated September 19, 2018 between Insurance Capital Group LLC and Enstar Holdings (US) LLC (incorporated by reference to Exhibit 10.9 to the Registrant’s Registration Statement on Form S-1 (333-229322)
10.10		Loan Agreement between Positive Physicians Holdings, Inc. and Diversus, Inc. dated March 27, 2019 (incorporated by reference to Exhibit 10.10 to the Registrant’s Annual Report on Form 10-K filed on April 24, 2019).
10.11		Medical Malpractice Working Excess Reinsurance Contract effective January 1, 2018 between Hannover Ruck Se and Professional Casualty Association (incorporated by reference to Exhibit 10.11 to the Registrant’s Registration Statement on Form S-1 (333-229322)).
10.12		Medical Malpractice Working Excess Reinsurance Contract effective January 1, 2018 between Hannover Ruck Se and Physicians’ Insurance Program Exchange (incorporated by reference to Exhibit 10.12 to the Registrant’s Registration Statement on Form S-1 (333-229322)).

Exhibit Number		Description
10.13		Non-Qualified Stock Option Agreement Between Positive Physicians Holdings, Inc. and Lewis Sharps, MD. (included by reference to Exhibit 10.1 filed with Form 8-K on October 2, 2019)
10.14		Offer Letter dated September 5, 2019, between Positive Physicians Holdings, Inc. and Donovan Augustin (included by reference to Exhibit 10.1 filed with Form 8-K on October 15, 2019)
31.1*		Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*		Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*		Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2*		Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema Document
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		XBRL Taxonomy Extension Label Linkbase Document
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

*	Filed herewith.

3635

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Positive Physicians Holdings, Inc.
Date: November 14, 2019	By:	/s/ Lewis S. Sharps, M.D.
Date: June 22, 2020	By:	/s/ Lewis S. Sharps, M.D.
		Lewis S. Sharps, M.D.
		President and Chief Executive Officer
Date: November 14, 2019	By:	/s/ Donovan C. Augustin
Date: June 22, 2020	By:	/s/ Donovan C. Augustin
		Donovan C. Augustin
		Chief Financial Officer

3736

Filing Compare · POSITIVE PHYSICIANS HOLDINGS, INC.